1999

NACDS Supports Need to Eliminate Rogue Internet Pharmacy Operators, Calls for Greater Enforcement of Existing Controls: PRNewswire - December 28, 1999; ALEXANDRIA, Va., Dec. 28 /PRNewswire/ -- In applauding efforts by the Clinton Administration to police rogue Internet pharmacy operators and rogue physicians, the National Association of Chain Drug Stores suggests new regulatory proposals should be carefully evaluated. The Administration s objective is laudable, and we
First-Ever 'Worldwide Beanie Baby Vote' to Generate Millions of Dollars For the Elizabeth Glaser Pediatric Aids Foundation; Ty Inc. Partners with Elizabeth Glaser Pediatric AIDS Foundation to Fund Scientific Research for Children Around-The-World with HIV/AIDS: PRNewswire - December 24, 1999; LOS ANGELES, Dec. 24 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation today was officially advised that it world receive all proceeds resulting from Ty Inc. s Worldwide Beanie Baby Vote beginning on Dec. 31. This first of its kind global vote will determine the fate of Beanie Babies worldwide. We extend o
Volunteers From Bay Area Jewish Community Lend a Hand to Feed 1,200 People With Aids and Seniors on Christmas Day: PRNewswire - December 23, 1999; For the eighth year in a row, nearly 100 representatives from Congregation Shav ar Zahav and Jewish Family and Children s Services will be preparing festive holiday meals for Project Open Hand clients. The preparation, packaging and delivery of over 1,200 holiday meals will be done by the Jewish community on both Chris
PricewaterhouseCoopers & CSC Help Launch angelwish.org for Kids Living with AIDS: PRNewswire - December 22, 1999; NEWARK, N.J., Dec. 22 /PRNewswire/ -- As millions of last minute shoppers attempt to log on to commercial Internet sites to find that special gift for a colleague or family member, PricewaterhouseCoopers is quietly promoting a community-enhancing alternative: a visit to angelwish.org. The site, which offers online visi
Internet Effective in Improving Patients' Compliance to Drug Treatment Schedules; Cyber Dialogue Study Suggests Avenues for Tackling Enduring Healthcare Challenge: PRNewswire - December 21, 1999; NEW YORK, Dec. 21 /PRNewswire/ -- The Internet provides powerful tools to help increase treatment compliance among people with chronic conditions, according to findings released today by Cyber Dialogue. Data from Cyber Dialogue s Cybercitizen Health survey of American adults found that one-third of chronic disease suff
Antiviral Drug Discovery & Development Conference to Feature Big Pharma Advances in Respiratory/Influenza, HIV, & HBV/HCV in March, in Princeton, NJ: PRNewswire - December 20, 1999; PRINCETON, N.J., Dec. 20 /PRNewswire/ -- A major new, international conference presenting the newest advances by the pharmaceutical industry in developing novel drugs to fight viral diseases, including respiratory/influenza, HIV, and hepatitis B & C, will take place on March 15-16, 2000 at the Hyatt Regency Hotel i
Hemispherx Announces New Approach to HIV Multi-Drug Resistance Test Results Show Potential Advantages of Immune Therapy When HIV Undergoes Massive Genetic Mutation: PRNewswire - December 16, 1999; PHILADELPHIA, Dec. 16 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that recent independent laboratory test results show potential advantages of its product Ampligen(R) when virologic failure occurs clinically with the presently available arsenal of anti-HIV drugs. According to findings
VX-175/GW433908, Vertex and Glaxo Wellcome HIV Protease Inhibitor In Clinical Development, Receives Fast Track Designation from U.S. FDA: PRNewswire - December 16, 1999; CAMBRIDGE, Mass., Dec. 16 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its partner Glaxo Wellcome has received fast track designation for the HIV protease inhibitor VX-175/GW433908 from the United States Food and Drug Administration. Fast track designation is granted to p
Study Published Today in The New England Journal of Medicine Demonstrates Potent and Sustained Anti-HIV Effect of a Regimen Containing Sustiva(TM) In Children: PRNewswire - Thursday, December 16, 1999; WILMINGTON, Del., Dec. 16 /PRNewswire/ -- An article published today in The New England Journal of Medicine (Volume 341, Number 25) concludes that combination HIV therapy with DuPont Pharmaceuticals Sustiva (TM) ( efavirenz ) plus nelfinavir and two nucleoside reverse transcriptase inhibitors ha
Drug Combination Shows Potent Punch Against HIV in Children, According To The Children's Hospital of Philadelphia: PRNewswire - December 15, 1999; PHILADELPHIA, Dec. 15 /PRNewswire/ -- A study headed by a physician at The Children s Hospital of Philadelphia has shown that a novel combination of drugs achieves strong, sustained results in controlling HIV infection in children, according to an article in the December 16 New England Journal of Medicine. Forty-eight
FDA Confirms Role of Hepatitis B Vaccine in Helping to Prevent Chronic Hepatitis B Infection Which Can Lead to Primary Liver Cancer: PRNewswire - December 14, 1999; PHILADELPHIA, Dec. 14 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has recognized the Centers for Disease Control and Prevention s (CDC) description of hepatitis B vaccines as preventing hepatitis B infections which can lead to primary liver cancer. SmithKline Beecham announced today that its Engerix-B
HIV, Flu & HBV/HCV Focus of Antiviral Drug Discovery Conference on March 15-16, 2000, in New Jersey: PRNewswire - December 8, 1999; PRINCETON, N.J., Dec. 8 /PRNewswire/ -- Pharmaceutical industry advances in the discovery and development of novel antiviral agents in HIV, influenza/respiratory, and hepatitis B & C, will be presented in depth on March 15-16, 2000 at the Hyatt Regency Hotel in Princeton, NJ, announces Strategic Research Institute.
Triangle Pharmaceuticals Announces That Additional Phase III Studies for Coactinon(R) (Emivirine) Are Required: PRNewswire - December 10, 1999; DURHAM, N.C., Dec. 10 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced that the Food and Drug Administration ( FDA ), following extensive discussions with the Company, has advised Triangle that it would need to conduct one or possibly two additional Phase III studies in order to prove that
CDC's NIOSH Alert and OSHA Directive on Needlesticks Met by New Safety IV Catheter That Protects Automatically: PRNewswire - December 9, 1999; BETHLEHEM, Pa., Dec. 9 /PRNewswire/ -- A new safety IV catheter that automatically shields the needletip after use could eliminate nearly 50,000 of the most dangerous accidental needlestick injuries faced by healthcare workers each year-those from hollow-bore IV needles that could be filled with blood containing infect
Chain Pharmacies Issue Statement Commenting on President Clinton's Proposals for Reducing Medical Errors: PRNewswire - Deccember 8, 1999; ALEXANDRIA, Virginia, Dec. 8 /PRNewswire/ -- The following statement is being issued by the National Association of Chain Drug Stores in response to President Clinton s announcement today of proposed measures to reduce medical errors. The statement is attributable to Craig L. Fuller, NACDS President and Chief Executive
AEGiS Honored as a Best of The Web Finalists for the 4th Annual GII Awards December 14th Gala Awards Ceremony to Feature Leaders in the Internet Economy; Peter Boit, Vice President, eCommerce, Business Solutions Group Microsoft Corporation to keynote, Comedienne Paula Poundstone and Jazz Great David Sanborn to Entertain: PRNewswire - December 7, 1999; SAN FRANCISCO, Dec. 7 /PRNewswire/ -- The Internet industry s premier awards program -- the prestigious Global Information Infrastructure (GII) Awards -- will recognize organizations that are utilizing the Internet to create a profound effect on the way that people live, work, learn and play. This year s winners will b
Ten Percent Funding Increase for More HIV/AIDS Services Announced by TPAC: PRNewswire - December 6, 1999; PHILADELPHIA, Dec. 6 /PRNewswire/ -- The Philadelphia AIDS Consortium today officially announced it was increasing its overall allocations to 51 community-based organizations by over $400,000. The increase for additional direct services to persons living with HIV/AIDS represents a 10% across-the-board hike to service p
Nelson Mandela, Bill Gates to Address Global Health Challenges Leaders Expected to Urge Businesses, Governments and Philanthropists to Help Improve Access to Medical Advances for Developing Nations 1999: PRNewswire - December 6, 1999; Former South African President Nelson Mandela will join Bill Gates, co- founder of the Bill and Melinda Gates Foundation, and others in a Forum that will address the challenges of providing access to lifesaving medical advances for children in the poorest parts of the world. WHEN: Thursday, December 9; 10:00 AM WHER
Providian Financial Announces $20,000 Grant to Support the Pediatric HIV Quality of Life Gift Fund: PRNewswire - December 3, 1999; SAN FRANCISCO, Dec. 3 /PRNewswire/ -- Providian Financial Corporation (NYSE: PVN) today announced that it has granted $20,000 to the Pediatric HIV Quality of Life Gift Fund, a nonprofit program administered by the UC San Francisco Pediatric AIDS Treatment Center. Established five years ago, the Fund is dedicated to mee
CASA to Release Study Revealing Dangerous Connection Between Teen Substance Use and Sex: PRNewswire - December 3, 1999; Teens who drink or use drugs are much more likely to have sex, initiate it at younger ages -- as early as middle school -- and have multiple partners, placing them at higher risk for sexually-transmitted diseases, AIDS and unplanned pregnancies, according to a new report to be released at 10 a.m. Tuesday, December 7 at
AMA Offers Good Health Tips for the New Millennium; A Strong Physician-Patient Relationship Will be Key in the Next Century: PRNewswire - December 2, 1999; CHICAGO, Dec. 2 /PRNewswire/ -- As we count down to the Year 2000, the physicians of America know that the new millennium will bring tremendous challenges and opportunities in preventing illness and disease. New technology, tests and treatments will result in more accurate diagnoses and better outcomes for patients. Gr
Healthcare Lawyers and Market Researchers Can Conduct Free Key Word Searches Among Internet's Largest Collection of Health and Hospital Case Law: PRNewswire - December 2, 1999; WALL, N.J., Dec. 2 /PRNewswire/ -- Healthcare lawyers, market researchers and information professionals can now conduct free full-text searches among the largest collection of health and hospital case law on the Internet through the Healthcare Intelligence Network (http://www.hin.com). Visitors to the site can search t
In Honor of World AIDS Day, Prendergast and Colthurst Announce New Website Discussing Drugs Developed to Treat HIV: PRNewswire - December 1, 1999; WASHINGTON, Dec. 1 /PRNewswire/ -- Colthurst Limited and Patrick T. Prendergast, Ph.D., inventors and developers of several drugs to treat HIV, announced today that they have established the website http://www.colthurst.org. The website will allow a wider audience access to scientific publications relating to HIV treat
African-American Leaders, Celebrities and Activists Fight AIDS Epidemic from the Inside Out; NIA Plan, the First Ever National Strategic Action Approach, Builds on Community Resources to Stop AIDS in African-American Communities: PRNewswire - December 1, 1999; LOS ANGELES, Dec. 1 /PRNewswire/ -- Congressional representatives, activists, civil rights leaders, celebrities, church and community leaders, and people living with AIDS, converged at a National Town Hall Meeting today -- World AIDS Day -- in Los Angeles to introduce a first-of-its-kind approach to fighting the AIDS e
Hughes Institute: Antiviral Agent Shows Promise in Treatment of AIDS: PRNewswire - December 1, 1999; ST. PAUL, Minn., Dec. 1 /PRNewswire/ -- Pokeweed antiviral protein, a natural product isolated from the pokeweed plant, shows great potential as a new anti-AIDS drug when targeted to cells infected with the AIDS virus. In a clinical study, nine out of nine patients were treated with a single dose of this agent and tole
Hollis-Eden Announces Preliminary Clinical Results from Phase I/II HIV Trial In South Africa With HE2000: PRNewswire - December 1, 1999; SAN DIEGO, Dec. 1 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced preliminary results from the first 13 patients treated with HE2000 in a Phase I/II HIV trial in South Africa . In this study, HE2000 administered as a monotherapy produced no serious drug-related adverse events and was ge
HIV/AIDS is City's Number One Health Problem, but 'Not In My Neighborhood' - Leading Community Groups Release Survey Results to Coincide with World AIDS Day -: PRNewswire - Tuesday, November 30, 1999; NEW YORK, Nov. 30 /PRNewswire/ -- New York City residents of all ages and ethnic backgrounds believe HIV/AIDS is the city s number one health problem according to a new survey of all five boroughs. More than half of the city s residents know one or more people that have died of AIDS or are currently living with AIDS or
Cable Industry Unites for World Aids Day 1999 On December 1st, and Throughout the Month, Hundreds of Cable Systems and Networks Will Telecast Aids-Related Programming and PSAs: PRNewswire - November 29, 1999; NEW YORK, Nov. 29 /PRNewswire/ -- NY-World AIDS Day is Wednesday, December 1, and every major network and cable system across the country is uniting to promote HIV/AIDS awareness by telecasting AIDS-related programming and public service announcements (PSAs). The goal of this coordinated effort is to reach millions of
The Elizabeth Glaser Pediatric AIDS Foundation Commemorates World AIDS Day at the United Nations: PRNewswire - November 30, 1999; NEW YORK, Nov. 30 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation is pleased to join the Magic Johnson Foundation for a symposium and other activities related to World AIDS Day at the United Nations. The day s theme, Children Left Behind, will focus on children from around the world who have been orphane
AIDS Healthcare Foundation to Relaunch West Hollywood 'Safer Sex City' Ballot Initiative: PRNewswire - November 30, 1999; Measure Requiring Condoms in West Hollywood Bars Revived As City Council Again Delays Compromise Action on Condoms Goal: Step up Prevention Efforts in West Coast Epicenter of HIV/AIDS WHAT: PRESS CONFERENCE/ Relaunch of Ballot Measure to Require Condoms in West Hollywood Bars AHF President Michael Weinstein, AHF s Gov
Keeping HIV Patients on Meds is Pharmacist's Goal at Abbott Northwestern Hospital: PRNewswire - November 30, 1999; MINNEAPOLIS, Nov. 30 /PRNewswire/ -- Bruce, a patient at Abbott Northwestern Hospital s Clinic 42, takes a combination of HIV medications three times a day. Currently, he takes four anti-retroviral medicines -- a total of ten pills, plus one liquid medicine -- to fight his HIV infection. HIV medications are complicated
Economists, AIDS Experts Highlight Major Impact of AIDS on Global Business and National Economies; amfAR Symposium at UN Hears Call for New Partnerships With Business to Combat Spread of AIDS Epidemic: PRNewswire - November 30, 1999; NEW YORK, Nov. 30 /PRNewswire/ -- At a high-level symposium at the United Nations this morning, business and economic experts predicted the AIDS story will soon move from the health pages to the business pages of the world s newspapers. Speaking at the Global Economics of HIV/AIDS: Defining Social and Business Costs sy
Eastern High School Students to Learn How to Live Smart in the Age of AIDS Through Award-Winning, Interactive Stage Play: PRNewswire - Tuesday, November 30, 1999; Kaiser Permanente Educational Theatre to Present Program that Provides Positive Role Models for Teens on World AIDS Day, December 1 WHAT: The Educational Theatre from Kaiser Permanente, Mid-Atlantic States, will perform Secrets, a live, 70-minute, interactive stage play about HIV/AIDS for 200 Eastern High School Studen
Therion Awarded AIDS Vaccine Manufacturing Contracts from NIH - Three agreements provide over $1.5 million in funding for development of novel vaccines and research products -: PRNewswire - November 29, 1999; CAMBRIDGE, Mass., Nov. 29 /PRNewswire/ -- Therion Biologics Corporation has been awarded three contracts totaling $1.5 million from the NIH s National Institute of Allergy and Infectious Disease (NIAID) for the development and manufacture of novel AIDS vaccines and related research reagents, the company announced today
FDA Approves Twice Daily Dosing (BID) of VIRACEPT(R) - Agouron's HIV Protease Inhibitor: PRNewswire - November 29, 1999; LA JOLLA, Calif., Nov. 29 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today announced that the Food and Drug Administration ( FDA ) has approved twice daily dosing (BID) of VIRACEPT(R) (nelfinavir mesylate) for the treatment of HIV infection. Approval supports 1250mg BID dosing of VIRACEPT based on data that showed c
The Children's Hospital of Philadelphia Celebrates World AIDS Day; Student Art and Essay Contest Winners Recognized at Awards Ceremony: PRNewswire - November 29, 1999; Who: Winners of the children s HIV/AIDS poster and essay contests will be recognized during a World AIDS Day ceremony at The Children s Hospital of Philadelphia. In addition, students from the School District of Philadelphia will entertain guests with music and dancing, while Teen Peer Educators from Children s Hospita
First AIDS Center to Open in West Philadelphia on World AIDS Day: PRNewswire - November 29, 1999; PHILADELPHIA, Nov. 29 /PRNewswire/ -- City officials and other invited guests will join We The People on World AIDS Day to open We The People West, the coalition s second neighborhood-based resource center for people living with HIV/AIDS in Philadelphia. Jannie Blackwell, in whose City Council District the project is l
World AIDS Day at UN Headquarters: 'The Children Left Behind' Looks at AIDS Orphans: PRNewswire - November 29, 1999; An observance of World AIDS Day, The Children Left Behind , will be held at UN Headquarters on 1 December 1999 from 10 a.m. to 6 p.m. in Conference Room 4. -- Speakers and participants include: Theo-Ben Gurirab, President of the UN General Assembly Kofi Annan, UN Secretary-General Louise Frechette, UN Deputy Secretary-
ActionAIDS Presents 'ART for LIFE' A Fine Arts Art Auction & Reception on the Eve of 'World AIDS Day' - A Day Without Art!: PRNewswire - November 27, 1999; PHILADELPHIA, Nov. 27 /PRNewswire/ -- INDEPENDENCE BLUE CROSS & INSIGNIA/ESG (Commercial Real Estate Corp) are the proud sponsors of the ActionAIDS -- ART for LIFE /Art Auction & Reception which will be held at IBC on Tuesday, November 30th, the Eve of World AIDS Day . ActionAIDS -- Pennsylvania s largest provi
Scientific Evidence Confirms Link Between HPV and Cervical Cancer; New England Journal of Medicine Suggests Screening for HPV: PRNewswire - November 26, 1999; BELTSVILLE, Md., Nov. 26 /PRNewswire/ -- An editorial published in the November 25 issue of The New England Journal of Medicine confirms that persistent human papillomavirus (HPV) infection causes cervical cancer and suggests that perhaps it is time to consider periodic screening for HPV in conjunction with screening f
UNAIDS Reports That AIDS Epidemic Not Slowing HIV Has Now Infected 50 Million Worldwide, With HIV-Positive Women Now Outnumbering Infected Men by 2 Million: PRNewswire - November 23, 1999; LOS ANGELES, Nov. 23 /PRNewswire/ -- According to a report released today by the Joint United Nations Programme on HIV/AIDS ( UNAIDS ) and the World Health Organization (WHO), since the beginning of the epidemic, 50 million individuals worldwide have been infected with HIV, of whom more than 16 million have died and 33
Bill and Melinda Gates Foundation Announces $750 Million Gift to Speed Delivery of Life-Saving Vaccines; Gift is Largest in Foundation's History: PRNewswire - November 23, 1999; SEATTLE, Nov. 23 /PRNewswire/ -- The Bill and Melinda Gates Foundation announced today a gift of $750 million over five years to help ensure that children in developing countries are immunized against major killer diseases in the new millennium. The gift represents the first contribution to a new initiative called the
Global Economic Impact of HIV/AIDS To Be Discussed at amfAR Symposium * World AIDS Day, December 1 *: PRNewswire - November 23, 1999; While research and prevention efforts have achieved considerable progress, nearly 40 million people are now living with HIV/AIDS worldwide, and 16,000 become newly infected each day. Because HIV primarily affects people during their most economically productive years, the increasing human and economic costs of the epid
World Wide Web, Government and Community Organizations Unite To Address Rising AIDS Epidemic in African-American Community With Unprecedented Satellite Conference; BlackFamilies.com Becomes the First African American Web Site to Take Stance On HIV/AIDS With Web Cast and More...: PRNewswire - November 23, 1999; ATLANTA, Nov. 23 /PRNewswire/ -- On November 30, the Surgeon General will host the African American Community HIV/AIDS Satellite Conference and BlackFamilies.com, the nation s premier Web site for African American families, will make history as the first black Web site to Web cast an event of this type. BlackFamilies.c
Queen, David Bowie and Microsoft Raise Funds to Fight AIDS Benefit to Begin on World AIDS Day, Dec. 1: PRNewswire - November 23, 1999; REDMOND, Wash., Nov. 23 /PRNewswire/ -- A three-way collaboration between Queen, David Bowie and Microsoft Corp. (Nasdaq: MSFT) will mark World AIDS day, Dec. 1, 1999, with a global Internet-based AIDS fund-raising event. Through WindowsMedia.com, the MSN(TM) online guide to multimedia on the Internet, Microsoft will h
National Football League Players Association Teams up With Outreach, Inc. To Tackle HIV/AIDS in the African-American Community: PRNewswire - November 23, 1999; WASHINGTON, Nov. 23 /PRNewswire/ -- The National Football League Players Association (NFLPA), in a bold off-the-field move, has teamed up with Outreach, Inc., in a series of Public Service Announcements (PSAs) designed to inform the public, particularly the African-American community, about the dramatic increase in HIV
Centers for Disease Control Issues Strong Alert to Advance Use of Safety Needles; Similar FDA Alert Resulted In Virtual Total Conversion to Safety of I.V. Administration Sets; Med-Design Sees CDC Alert as Further Evidence for Complete Conversion To Safety Needles: PRNewswire - November 23, 1999; VENTURA, Calif., Nov. 23 /PRNewswire/ -- The Med-Design Corporation (Nasdaq: MEDC) announced today that The Centers for Disease Control (CDC) issued a very strongly worded safety alert yesterday advocating that all hospitals and other health care facilities use safety needles to protect health care workers from deadly
Project Open Hand's Caring Cuisine Graces the Plates of Hundreds of Men, Women And Children in the Bay Area This Thanksgiving: PRNewswire - November 22, 1999; SAN FRANCISCO, Nov. 22 /PRNewswire/ -- Project Open Hand s work and its mission -- Meals with Love -- takes on special resonance during Thanksgiving, the holiday so closely associated with food. The kitchen at 730 Polk Street in San Francisco will be buzzing with activity as staff and volunteers prepare more than 800 t
Boston Biomedica Awarded $9.6 Million AIDS Repository Contract: PRNewswire - November 22, 1999; WEST BRIDGEWATER, Mass., Nov. 22 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) announced today that BBI Biotech Research Laboratories (a wholly-owned subsidiary of Boston Biomedica) has been awarded a seven year $9.6 million specimen repository contract from the National Institute of Allergy and Infectious Dise
National PTA World Aids Day Web Site Offers Resources, Interactive Features: PRNewswire - November 22, 1999; CHICAGO, Nov. 22 /PRNewswire/ -- AIDS prevention, state hotline numbers, and tips for talking about AIDS with children are just a few of the features on National PTA s web site devoted to the topic at http://www.pta.org/events/wad99 . For the third consecutive year, National PTA is providing these materials in anticipa
The Health Network to Participate in World AIDS Day Leading Television Health Network and Internet Site to Show Original AIDS-related Programming and Content and Join in Cable Positive Programming and Events, December 1, 1999: PRNewswire - November 22, 1999; ORLANDO, Fla., Nov. 22 /PRNewswire/ -- The Health Network, the leading health destination on television and the Internet, will join Cable Positive, the cable industry s AIDS action organization, to increase awareness of HIV and AIDS on World AIDS Day, December 1, 1999. AIDS is now the second leading cause of death amon
CEL-SCI Announces Data from Phase II HIV Vaccine Study HGP-30W Is the Only AIDS Vaccine in Human Studies Designed to Work Against Subtype C, the Most Prevalent HIV-1 Subtype in the Developing World: PRNewswire - November 22, 1999; VIENNA, Va., Nov. 22 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: HIV) (Berlin Stock Exchange: LSR), in response to media questions in advance of World AIDS Day, releases the following statement. Frequently asked questions and answers are as follows: ** Do you have any results from your phase II HIV vaccine study? The HG
Ohio Commemorates World AIDS Day at Statewide Conference: PRNewswire - November 22, 1999; CLEVELAND, Nov. 22 /PRNewswire/ -- The Ohio Department of Health HIV/STD Prevention Program will commemorate World AIDS Day with a 2-day conference, End the Silence, on December 6 and 7, 1999, at the Fawcett Center on the Ohio State University campus in Columbus. The conference schedule includes five plenary sessions a
World AIDS Day at UN Headquarters: 'The Children Left Behind' Looks at AIDS orphans: PRNewswire - November 20, 1999; An observance of World AIDS Day, The Children Left Behind, will be held at UN Headquarters on 1 December 1999 from 10 a.m. to 6 p.m. -- Speakers and participants include: Theo-Ben Gurirab, President of the UN General Assembly Kofi Annan, UN Secretary-General Louise Frechette, UN Deputy Secretary-General Hillary Clinton
Latest HIV/AIDS Treatment Information Now Available Online amfAR Launches Online Version of HIV/AIDS Treatment Directory: Experimental Treatments and Clinical Trial Locations Searchable by CD4+ Counts, Viral Loads: PRNewswire - November 19, 1999; PHILADELPHIA, Nov. 19 /PRNewswire/ -- Health care providers and anyone affected by HIV can now access the latest information on approved and experimental HIV therapies online, it was announced today. The American Foundation for AIDS Research (amfAR) HIV/AIDS Treatment Directory, long considered one of the most comprehe
World's Top Fashion Designers Create One-of-a-Kind Paddington Bears To Benefit Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - November 19, 1999; WHAT: In honor of Paddington Bear s 40th anniversary the Council of Fashion Designers of America presents a private VIP shopping spree at FAO Schwarz to benefit Elizabeth Glaser Pediatric AIDS Foundation Highlight of evening is live auction of Paddington Bear designed by Badgley Mischka WHO: On display will be Paddingt
Immtech Announces Start of Large-Scale Recombinant mCRP (rmCRP) Production Phase for Human Clinical Trials: PRNewswire - November 18, 1999; VERNON HILLS, Ill., Nov. 18 /PRNewswire/ -- Immtech International, Inc. (Nasdaq: IMMT) a biopharmaceutical company focused on the discovery and commercialization of pharmaceutical treatments for infectious diseases such as tuberculosis, fungal diseases, pneumonia and diarrhea, and biological products to treat cancer an
Myriad Genetics Identifies New HIV Drug Target - Novel Assay for Therapeutic Target Holds Promise for Improved AIDS Drugs -: PRNewswire - November 18, 1999; SALT LAKE CITY, Nov. 18 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has identified a novel drug target for the treatment of HIV. The drug target represents a new approach to treating AIDS, and may enable the creation of an entirely new class of therapeutics, distinct from the
More Than 100,000 Youth Age 13-21 are Projected to be HIV Positive in United States; African American and Latino Youth Represent 62% of New Infections Six-City Campaign Responds to Health Emergency Promoting HIV Counseling, Testing and Care: PRNewswire - November 17, 1999; NEW YORK, Nov. 17 /PRNewswire/ -- It is estimated that as many as 100,000 young people in the United States between the ages of 13 and 21 are infected with HIV and most don t know it and are not receiving necessary life-prolonging health care. HIV. LIVE WITH IT. GET TESTED! a campaign that speaks directly to youth in t
Levi's(R) Jeans & Lifebeat Present 'Music with a Message: World AIDS Day 1999' Benefit Concert Featuring 'NSYNC, Monica, Wyclef Jean and Destiny's Child; Live Webcast on levi.com to Support Global AIDS Awareness Campaign: PRNewswire - November 17, 1999; NEW YORK, Nov. 17 /PRNewswire/ -- In celebration of World AIDS Day 1999, Levi s(R) Jeans and LIFEbeat, the Music Industry Fights AIDS, have partnered to present Music with a Message: World AIDS Day 1999, a benefit concert on December 1 to support HIV/AIDS education. Marking the twelfth anniversary of World AIDS Day, mu
Senate Bill 677 to Increase Access to Health Care for Low Income Older Adults and People with Disabilities; Senator Christine Radogno Announces Plan to Help Pay For High Medical Costs Including Prescription Drugs: PRNewswire - November 16, 1999; SPRINGFIELD, Ill., Nov. 16 /PRNewswire/ -- State Senator Christine Radogno (R-24, LaGrange) announced a bi-partisan plan to address the health care needs of low-income older and adults and people with disabilities. The plan -- dubbed the 100% Campaign -- will increase access to Illinois state Medicaid program. Senator
Ushercell Successfully Completes Phase I Human Clinical Trial of Polydex AIDS, STD Contraceptive Drug: PRNewswire - November 16, 1999; TORONTO, Nov. 16 /PRNewswire/ -- Polydex Pharmaceuticals Ltd. (Nasdaq: POLXF) (BSE: PXL) is pleased to report that Phase I, safety and tolerance clinical study of Ushercell, was successfully completed with minimal evidence of vaginal irritation, by the Contraceptive Research and Development (CONRAD) Program. The projec
Half a Million Californians in Jeopardy; Hearing on Hep C Reveals California Is Unprepared for Latest Public Health Epidemic: PRNewswire - November 12, 1999; LOS ANGELES, Nov. 12 /PRNewswire/ -- A California Senate Hearing on hepatitis C today reviewed the Department of Health Services (DHS) and Department of Corrections handling of a little known, but deadly and pervasive virus -- hepatitis C. The spotlight revealed little action has been taken by either department to stop
Data Safety Monitoring Board Recommends Completion of a Phase II Remune Trial in Spain of Patients Infected With HIV: PRNewswire - November 4, 1999; CARLSBAD, Calif., Nov. 4 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced that an independent Data Safety Monitoring Board (DSMB) composed of European and U.S. scientists recommended that the trial in Spain of Remune(TM) (trial 2102) in patients infected with HIV continue to its conclusion
Increasing the Reach of HIV Information: WebMD and the National Minority AIDS Council Join Together for Live Webcast of Nation's Largest Community Conference on AIDS; For the First Time Ever, the United States Conference on AIDS Is Accessible via the Internet: PRNewswire - November 4, 1999; DENVER, Nov. 4 /PRNewswire/ -- WebMD and the National Minority AIDS Council (NMAC) have partnered to bring the third annual United States Conference on AIDS (USCA) to the Internet, beginning today. For the duration of the conference, WebMD will conduct live Webcasts of keynote speakers and plenary sessions via http://a
Parliament of World's Religions Opening Ceremonies Show Relevance to South Africa, World: PRNewswire - November 4, 1999; CHICAGO, Nov. 4 /PRNewswire/ -- Opening day ceremonies for the 1999 Parliament of the World s Religions will symbolize the relevance of religion and spirituality to issues facing South Africa and the world. The Dec. 1-8 event is expected to draw some 6,000 people from around the globe to Cape Town, South Africa s show
The Immune Response Corporation Presents Data Suggesting That Remune May Have an Effect on the Control of HIV Infection: PRNewswire - November 3, 1999; CARLSBAD, Calif., Nov. 3 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that data were presented at the Royal College of Physicians, London, England, showing that patients treated with REMUNE(TM), an immune-based therapy to treat HIV infection, exhibited a significant increase in lymphoc
Hollis-Eden Pharmaceuticals to Present Clinical Data on HE2000 at HIV Conference: PRNewswire - November 3, 1999; SAN DIEGO, Nov. 3 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced that clinical data from studies with its lead compound, HE2000, will be presented at the 4th International Workshop on HIV, Cells of Macrophage Lineage, and other Reservoirs, to be held in Florence, Italy De
Rates of HIV Infection and AIDS-Related Deaths Drop Among the Nation's Prisoners: PRNewswire - November 3, 1999; WASHINGTON, Nov. 3 /PRNewswire/ -- The rate of human immunodeficiency virus (HIV) infection among state and federal prisoners dropped from 2.3 percent in 1996 to 2.1 percent in 1997, according to a new bulletin released today by the Justice Department s Bureau of Justice Statistics (BJS). There were 23,548 HIV-infected
Oak Brook Physician Leads Effort Raising $100,000 For Parliament of the World's Religions: PRNewswire - October 29, 1999; CHICAGO, Oct. 29 /PRNewswire/ -- Oak Brook resident Dr. Biswamay Ray, chairman of the annual fund raising dinner for the Council for a Parliament of the World s Religions (CPWR), reports that the organization netted some $100,000 from this year s event, held Sunday, Oct. 24, at Chicago s Palmer House Hilton. When the d
Centers for Disease Control Joins VaxGen Study; Awards $8 Million Contract to Supplement HIV Vaccine Research: PRNewswire - October 29, 1999; BRISBANE, Calif., Oct. 29 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) today announced that the federal Centers for Disease Control and Prevention (CDC) will contribute funds to support additional research at five of the 56 clinics in the United States currently conducting Phase III clinical trials of VaxGen s AIDSVA
Schering-Plough Researchers Identify Promising Drug Targets in Hepatitis C Virus: PRNewswire - October 28, 1999; MADISON, N.J., Oct. 28 /PRNewswire/ -- In a potentially major step against a lethal infectious disease, scientists at Schering-Plough Research Institute have identified the structure of an enzyme complex that is essential to replication of the hepatitis C virus (HCV). In an article published in the November issue of St
Advertising Community Bands Together to Raise Money for AIDS Charities At the Third Annual Madison Avenue Sellout; Ivana Trump Joins the Cause at November 3, 1999 Event To Be Held At The Tent at Lincoln Center: PRNewswire - October 27, 1999; NEW YORK, Oct. 27 /PRNewswire/ -- For the third consecutive year, the advertising industry will host the Madison Avenue Sellout, an auction and garage sale of products and services donated by the advertising community to benefit AIDS services. The Madison Avenue Sellout will be held on November 3, 1999 at the Tent at L
New Educational Video Offers Support to People of Color Living with HIV: PRNewswire - October 27, 1999; WASHINGTON, Oct. 27 /PRNewswire/ -- MEE (Motivational Educational Entertainment) Productions Inc., an internationally-recognized communications firm targeting urban populations, has debuted its latest video production, Life is What You Make It(TM), designed to raise awareness of HIV/AIDS treatment options within Americ
New Center to Promote Quality VA Care for HIV: PRNewswire - October 26, 1999; WASHINGTON, Oct. 26 /PRNewswire/ -- The Department of Veterans Affairs (VA) is launching a new Center for Quality Management in HIV Care, a national working laboratory in Palo Alto, Calif., designed to promote innovation and improvement in the care of patients infected with the human immunodeficiency virus, which cause
Triangle Pharmaceuticals Presents Data From Pivotal Study Of Coactinon(R) (Emivirine) In Treatment-Naive, HIV-Infected Patients - Data Presented at 7th European Conference on Clinical Aspects And Treatments of HIV Infection in Lisbon -: PRNewswire - October 26, 1999; DURHAM, N.C., Oct. 26 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that it will present 24-week data from MKC 301, a pivotal study designed to assess the antiviral activity, safety and tolerability of Coactinon(R) (emivirine), formerly known as MKC-442, in treatment-naive HIV-infected p
Agouron Acquires Rescriptor From Pharmacia & Upjohn; Non-Nucleoside Reverse Transcriptase Inhibitor Adds to Agouron's HIV Portfolio: PRNewswire - October 25,1999; LA JOLLA, Calif., and PEAPACK, N.J., Oct. 25 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. and Pharmacia & Upjohn , Inc. (NYSE: PNU) today announced that Agouron has acquired worldwide rights to Pharmacia & Upjohn s RESCRIPTOR(R) ( delavirdine mesylate tablets),
Five Borough Youth Campaign Responds to Health Emergency Bringing HIV Counseling, Testing, and Care to Young People at Risk African American and Latino Youth Represent 62% of New HIV Infections Among Youth 13-24; Half of All AIDS Cases: PRNewswire - October 25, 1999; NEW YORK, Oct. 25 /PRNewswire/ -- It is estimated that at least 10,000 young people in New York City ages 13-24 are infected with HIV and most don t know it. HIV. LIVE WITH IT. GET TESTED!, an innovative campaign that speaks directly to young people in their own language, is being launched in response to this health em
1999 United States Conference on AIDS, Largest AIDS Meeting in the U.S., Will Bring 3000 Front-Line Professionals to Denver, November 4-November 8 Sponsored By the National Minority AIDS Council, Conference Will Focus On Working Together in the Fight Against HIV/AIDS Both Locally and Globally: PRNewswire - October 12, 1999; WASHINGTON, Oct. 12 /PRNewswire/ -- Exploring the concept of working together -- both locally and globally -- will be the theme of the largest AIDS meeting in the United States -- the United States Conference on AIDS (USCA), scheduled for November 4-8 in Denver Colorado. More than 3,000 representatives from the nation
CDC Advisory Committee Votes to Recommend First Pneumococcal Conjugate Vaccine for Routine Use in Children: PRNewswire - October 22, 1999; ATLANTA, Oct. 22 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously today to recommend Prevenar(, the first pneumococcal conjugate vaccine, for routine use in all healthy children up to age 5 with priority use in specific population
Nabi(R) Files Canadian Application for Nabi-HB(TM): PRNewswire - October 21, 1999; BOCA RATON, Fla., Oct. 21 /PRNewswire/ -- Nabi (Nasdaq: NABI) announced today that it has filed a New Drug Submission (NDS) with the Canadian regulatory authorities for Nabi-HB, Hepatitis B Immune Globulin (Human), in Canada . Nabi has been notified that this application will receive Priority Review. Upon completion o
First International Conference on Aids in Ethiopia Set For November: PRNewswire - October 21, 1999; CAMBRIDGE, Mass., Oct. 21 /PRNewswire/ -- The First International Conference on AIDS in Ethiopia is set to take place in Addis Ababa from November 6 - 10, 1999. The conference, organized under the banner Fighting for Life will bring together AIDS experts from around the world to discuss the expanding problem of AIDS in
Study Shows Efficacy of Oral Antiviral Hepatitis B Treatment: PRNewswire - October 21, 1999; RESEARCH TRIANGLE PARK, N.C., Oct. 21 /PRNewswire/ -- Patients with chronic hepatitis B who were treated with the oral antiviral medication Epivir (R)-HBV(TM) (lamivudine) were more likely than patients receiving placebo (sugar pill) to experience improvements in liver inflammation and other signs of hepatitis B virus
Ambion Awarded Grant to Further Develop Armored RNA(R) Technology: PRNewswire - October 20, 1999; AUSTIN, Texas, Oct. 20 /PRNewswire/ -- Ambion, Inc. has been awarded a phase II SBIR grant for $808,000 from the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of their Armored RNA(R) technology. The main application of this technology is to manufacture stable, robust RNA that
750 Los Angeles County Residents Take Off to Run the Marine Corps Marathon in Washington DC; LA Runners Raise More than $2.6 Million to Support Men, Women And Children Living with HIV and AIDS: PRNewswire - October 20, 1999; LOS ANGELES, Oct. 20 /PRNewswire/ -- On Friday, October 22, 750 people from Southern California will board United Airlines flights taking them to Washington DC to run the Marine Corps Marathon on Sunday, October 24. Most of the runners are first time marathoners, some living with HIV, some running in memory of loved on
The Children's Hospital of Philadelphia Kicks Off HIV Get Tested Week; Youth Town Meeting Held at the Community College of Philadelphia: PRNewswire - October 20, 1999; What: To kick off Get Tested Week, the Adolescent HIV Initiative at The Children s Hospital of Philadelphia will host a Youth Town Meeting entitled The Miseducation of Generation X -- HIV and AIDS: What you need to know. Who: Youths between the ages of 13 and 24 are invited to attend this high-energy event. Bret Rudy,
South Africans to Address Annual Dinner For Parliament of the World's Religions: PRNewswire - October 20, 1999; CHICAGO, Oct. 20 /PRNewswire/ -- Two prominent South Africans will address the annual dinner for the Council for a Parliament of the World s Religions (CPWR). More than 500 supporters will attend the annual event, to begin at 5:30 p.m., Sunday, Oct. 24, at Chicago s Palmer House Hilton. The South Africans -- one a lead
American & Russian Scientists Team Up to Fight Tuberculosis Threat Argonne-Engelhardt Biochip Designed to Improve Diagnosis Of Drug-Resistant Disease and Point Researchers Toward New Treatment Options: PRNewswire - October 20, 1999; ARGONNE, Ill., Oct. 20 /PRNewswire/ -- A new biochip technology developed by American and Russian scientists may help stem the global resurgence of tuberculosis. The technology, developed by the U.S. Department of Energy s Argonne National Laboratory and the Russian Academy of Sciences Engelhardt Institute of Molecular
CEL-SCI Reports Encouraging Clinical Findings in HIV-Infected Patients: PRNewswire - October 19, 1999; VIENNA, Va., Oct. 19 /PRNewswire/ -- CEL-SCI Corporation (Amex: HIV; Berlin Stock Exchange: LSR) announced today that independent investigators at AIDS ReSEARCH Alliance, West Hollywood, California, have completed a clinical study using CEL-SCI s Multikine(TM) to determine primarily its safety, and secondarily its abil
Mallinckrodt to Supply Peptide to Trimeris for Novel AIDS Therapeutic: PRNewswire - October 18, 1999; ST. LOUIS, Oct. 18 /PRNewswire/ -- Mallinckrodt Inc. (NYSE: MKG) announced today it has signed an agreement with Trimeris Inc. (Nasdaq: TRMS), Durham, N.C., to supply large-scale quantities of an investigational peptide, T-20, for use in continuing clinical trials for a novel therapeutic for the treatment of the human
APLA Supports City's Proposal to Fund Housing-Related Programs for Persons Living with HIV/AIDS: PRNewswire - October 15, 1999; LOS ANGELES, Oct. 15 /PRNewswire/ -- AIDS Project Los Angeles (APLA) supports the recent allocation of $8.7 million proposed by the Los Angeles Housing Department (LAHD) for the Housing Opportunities for Persons with AIDS (HOPWA) program. We are pleased that the City is moving forward and are hopeful that this proposal
Needle Destruction Units Authorized for Use in California; Hypodermic Needle Destruction Unit to be Marketed by Remel Inc. Regulations to Ensure Healthcare Workers Access to Advanced Technology: PRNewswire - October 14, 1999; ATLANTA, Oct. 14 /PRNewswire/ -- Biomedical Disposal, Inc. (Biomed) of Norcross received formal notification from California s Occupational Safety and Health Standards Board (Cal/OSHA) that use of advanced technology needle destruction units was authorized and encouraged as a method of compliance to that state s bloodb
HIV Experts Convene in Atlanta for Regional Conference on HIV/AIDS in the African-American Community -HIV/AIDS Experts Representing the Public Health and Medical Community Join Together to Address Current Health Crisis-: PRNewswire - October 14, 1999; ATLANTA, Oct. 14 /PRNewswire/ -- A regional conference that brings together experts from the public health sector, AIDS service organizations, and medical providers will convene in Atlanta to focus on HIV/AIDS in the African-American community. The conference is the fourth in a series of updates to the inaugural Nation
The Immune Response Corporation Publishes Data in Proceedings of the National Academy of Sciences Suggesting a Correlation Between HIV-specific Immune Responses and Favorable Clinical Status; High Levels of HIV Inhibitory B-chemokines and Lymphocyte Proliferation Associated With AIDS-free Status: PRNewswire - October 14, 1999; CARLSBAD, Calif., Oct. 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced the publication of data from a Multicenter AIDS Cohort Study in collaboration with the Institute of Human Virology and Johns Hopkins University examining immune response correlates of AIDS-free status in HIV-infecte
Regional Update Conference on African-Americans and AIDS Atlanta, October 14th, 1999: PRNewswire - October 14, 1999; Regional Update Conferences on African-Americans and AIDS have been organized to focus on HIV/AIDS in the African-American community. What: Leading AIDS experts from the medical, research, government and public health sectors will address a wide range of issues relating to African-Americans and AIDS. Presentations at t
BellSouth Mobility, a Grand Sponsor of AIDS Walk Atlanta, Wants You to Walk; Lace Up Your Shoes and Walk For Life: PRNewswire - October 13, 1999; ATLANTA, Oct. 13 /PRNewswire/ -- Over 15,000 people in metro Atlanta are currently living with AIDS, and 11,347 Georgia area residents have died because of the disease since 1981. On Sunday, October 17th, thousands of Atlantans will gather at Piedmont Park to take part in the annual AIDS Walk Atlanta. Proceeds from the
Chronimed to Manage FDA Clinical Trials for Visible Genetics' HIV Genotyping Test: PRNewswire - October 13, 1999; MINNEAPOLIS, Oct. 13 /PRNewswire/ -- Chronimed Inc. (Nasdaq: CHMD), announced today that it has signed a contract with Visible Genetics Inc. (Nasdaq: VGIN) whereby Chronimed s wholly-owned subsidiary, Clinical Partners, will manage Visible Genetics prospective multi-center, controlled clinical trial of genotyping assis
NAACP Launches National Awareness Campaign to Address HIV/AIDS Epidemic Among African-Americans; Films Supported by DuPont Pharmaceuticals and AT&T Broadband & Internet Services: PRNewswire - October 13, 1999; WHAT: The National Association for the Advancement of Colored People (NAACP) will unveil an educational film series aimed at addressing the growing epidemic of HIV/AIDS in the African- American community. Developed in partnership with DuPont Pharmaceuticals and AT&T Broadband & Internet Services (AT&T BIS),
AIDS Project Los Angeles Commends Governor Davis for Signing Two Important HIV/AIDS Bills APLA Urges Funding for HIV Surveillance After AD 103 Vetoed: PRNewswire - October 12, 1999; LOS ANGELES, Oct. 12 /PRNewswire/ -- AIDS Project Los Angeles (APLA) commends Governor Gray Davis for signing two important HIV/AIDS bills -- AB 155 and AB 136. AB 155 directly impacts the lives of people living with AIDS by assisting those who may be well enough to work, enter or reenter the workforce. AB 103 will all
VaxGen Inoculates 5,000 Volunteers in U.S. Trial of HIV Vaccine Investment by Paul Allen Raises $25 Million for Global Vaccine Effort: PRNewswire - October 12, 1999; BRISBANE, Calif., Oct. 12 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) today announced that it has inoculated more than 5,000 volunteers, completing enrollment in the United States portion of the North American trial of AIDSVAX(R), a vaccine designed to prevent infection by HIV. Additionally, the company announced it
Hemispherx and Anderson Clinical Research to Combine Forces in New Initiative Against HIV Drug Resistant Strains: PRNewswire - October 12, 1999; PHILADELPHIA, Oct. 12 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that it was developing clinical programs with Anderson Clinical Research that are designed to address the growing problem of multi-drug resistance found in battling the AIDS epidemic both in the U.S. and worldwide. The p
Targeted Outreach and Service Techniques Improve Retention of Women in HIV/AIDS Clinical Trials; Providing Transportation and Child Care Are Most Important, According to Pilot Project: PRNewswire - October 11, 1999; LOS ANGELES, Oct. 11 /PRNewswire/ -- As more women become infected with HIV and as it becomes more important to test new treatments on women, a pilot project suggests that targeted outreach and service techniques dramatically increase the enrollment and retention of women participating in HIV-related clinical trials. T
New Database on HIV/AIDS to Focus on Real-World Treatment Outcomes: PRNewswire - October 11, 1999; SAN FRANCISCO, Oct. 11 /PRNewswire/ -- A new HIV/AIDS database being developed at UC San Francisco is designed to serve as a centralized location for real-world treatment outcomes and as a resource for the international medical community in treating HIV disease. The system is named HIVWatch. The UCSF Positive Health Pr
Largest Clinical Trial to Review Sex Differences in HIV Treatment Announced at National Conference on Women and HIV/AIDS 'A.T. L.A.S.T.' Clinical Trial Designed by Investigators, Bristol-Myers Squibb and Women Alive: PRNewswire - October 11, 1999; LOS ANGELES, Oct. 11 /PRNewswire/ -- Details of the largest clinical trial to closely determine sex differences in HIV treatment were presented today at the 1999 National Conference on Women and HIV/AIDS, being held at the Los Angeles Convention Center. The A.T. L.A.S.T. (Antiretroviral Trial Looking at Sex and Treatme
SciClone Receives Second Key U.S. Patent for Use of ZADAXIN(R) To Treat Hepatitis C: PRNewswire - October 7, 1999; SAN MATEO, Calif., Oct. 7 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN), today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the Company s second U.S. patent covering the use of its lead drug, ZADAXIN, to treat hepatitis C. ZADAXIN boosts the immune system in the fig
National Health Association Testifies On Medicare Limits For Rehabilitation Services: PRNewswire - October 8, 1999; WASHINGTON, Oct. 8 /PRNewswire/ -- A $1,500 cap on outpatient therapy hinders access to much needed rehabilitation treatment by Medicare beneficiaries according to testimony made by the American Speech-Language- Hearing Association (ASHA) on October 1, 1999. Speaking before the Subcommittee on Health of the House Ways
Datamonitor Predicts HIV Drugs Sustiva and Combivir Will Boost Patient Life Quality and Battle Increasing Non-compliance: PRNewswire - October 8, 1999; NEW YORK, Oct. 8 /PRNewswire/ -- After surveying 100 HIV specialists in North America, Latin America and Europe, Datamonitor found that Sustiva and Combivir were rated as the best new drugs to address patient compliance. The survey also revealed that specialists rate patient compliance as
Pharmaceutical Resources Files ANDA Submission for Megestrol Acetate Oral Suspension: PRNewswire - October 8, 1999; SPRING VALLEY, N.Y., Oct. 8 /PRNewswire/ -- Par Pharmaceutical, a wholly owned subsidiary of Pharmaceutical Resources, Inc. ( PRI ) (NYSE: PRX; PCX), has filed an abbreviated new drug application (ANDA) for megestrol acetate oral suspension with the FDA . Par believes that it was the first company to have its ANDA acce
Regional Update Conference on African-Americans and AIDS Atlanta, October 14th, 1999: PRNewswire - October 8, 1999; Regional Update Conferences on African-Americans and AIDS have been organized to focus on HIV/AIDS in the African-American community. What: Leading AIDS experts from the medical, research, government and public health sectors will address a wide range of issues relating to African-Americans and AIDS. Presentations at t
AIDS Memorial Quilt to Cape Town for Parliament of World's Religions: PRNewswire - October 8, 1999; CHICAGO, Oct. 8 /PRNewswire/ -- The AIDS Memorial Quilt is going to the 1999 Parliament of the World s Religions in Cape Town, South Africa , the first week of December. The largest Quilt display ever taken to South Africa, more than 1,000 panels naming those who have died from the disease, will be presented on the Par
Triangle Pharmaceuticals Announces Modification of its Clinical Study MKC-303: PRNewswire - October 7, 1999; DURHAM, N.C., Oct. 7 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced the modification of its clinical Study MKC-303 relating to Coactinon(R) (emivirine), formerly known as MKC-442. All patients will be offered the opportunity to stay on Coactinon with or without nelfinavir, or change to a
A 'Shaky' Start 10 Years Ago Did Not Falter Project Open Hand's Alameda County Services: PRNewswire - October 6, 1999; PRNewswire - OAKLAND, Calif., Oct. 6 /PRNewswire/ -- It was October 17, 1989 and Project Open Hand was set to start delivering Meals with Love to People with AIDS in Alameda County. The organization had already been providing nutritious, home delivered meals in San Francisco for four years and was furthering its reach
Why Life?: UNICEF Pressures Kenyan Leaders To Push Failed Youth Sex Ed Programs: PRNewswire - October 6, 1999; WASHINGTON, Oct. 6 /PRNewswire/ -- The United Nations Children s Fund (UNICEF) is turning its back on the truth by pushing sex education programs on the youth of Kenya , said Mark DeYoung, director of Why Life? Isn t it about time we learn from the mistakes of the past? These programs are doomed for failure. There is n
amfAR Symposium: Anti-AIDS Gels Urged by Researchers & Health Experts Leading Researchers and Women's Health Experts Urge Development of Anti-AIDS Gels for Women; Latest Research and Data Presented at amfAR Symposium: PRNewswire - October 6, 1999; NEW YORK, Oct. 6 /PRNewswire/ -- To reduce the spread of HIV around the globe, leading researchers and health experts at a symposium sponsored by the American Foundation for AIDS Research (amfAR) have urged the development of gels and other natural substances that women can use to block HIV transmission. Called microbi
Good News For Orange Juice Drinkers: Harvard Study Finds Certain Fruits and Vegetables May Reduce Risk of Stroke by 30 Percent: PRNewswire - October 6, 1999; CAMBRIDGE, Mass., Oct. 6 /PRNewswire/ -- All fruits and vegetables are not created equal. That s what a recent Harvard University study published in the October 6 issue of the Journal of the American Medical Association (JAMA) confirms. Researchers at Brigham and Women s Hospital (BWH) and Harvard School of Public Heal
New Studies Show Progenics Drug to Be Potent HIV Inhibitor: PRNewswire - October 5, 1999; BETHESDA, Md., Oct. 5 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today reported that its product, PRO 140, possesses potent and broad-spectrum anti-HIV activity. PRO 140 is a promising new compound that inhibits HIV entry via a novel mechanism. These findings, from a preclinical study carried out in
Leadership Conference of Public and Correctional Health Officials to Discuss the More Than 50,000 Inmates with HIV/AIDS - Experts to Develop First-Ever Guidelines on Growing Health Emergency in U.S. Jails -: PRNewswire - October 4, 1999; CHICAGO, Oct. 4 /PRNewswire/ -- Correctional health officials from 17 of the nation s jails are meeting in Chicago, with their public health counterparts, in a landmark meeting to address the growing health emergency in prisons created by HIV/AIDS and other infectious diseases. During the meeting Rev. Jesse Jackson, Sr
Expanded Role for Female Condom Demanded in Global War Against AIDS The Female Health Company Introduces Turn-Key Prevention Guide at African AIDS Conference: PRNewswire - October 4, 1999; CHICAGO, Oct. 4 /PRNewswire/ -- The female condom is now positioned to play a critical role in winning the global war on AIDS, Mary Ann Leeper, Ph.D., president of the U.S.-based Female Health Company (OTC Bulletin Board: FHCO), announced at the recent International Conference on AIDS and STDs in Africa (ICASA). The Se
U.K. Government Study Supports the Use of HPV Testing in the Detection of Cervical Cancer - Results Provide Mounting Evidence to Support HPV Testing in Cervical Screening -: PRNewswire - October 1, 1999; BELTSVILLE, Md., Oct. 1 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE) announced today that a government report in the United Kingdom , published today by the Imperial Cancer Research Fund, has backed testing for human papillomavirus (HPV), the cause of cervical cancer, as part of the National Cervical Screening Pro
Biochem Pharma Announces China Launch of Heptodin (Lamivudine) for Hepatitis B: PRNewswire - October 1, 1999; LAVAL, Quebec, Canada , Oct. 1st /CNW-PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE; ME, TSE: BCH) announces the launch of Heptodin (lamivudine), the world s first oral antiviral treatment for chronic hepatitis B, in China , which has the highest prevalence of the disease in the world. Heptodin, known as Zeffix in most cou
Experts Seek Solutions for Better Management of HIV/AIDS Treatment Clinical and Policy Experts Focus on Integrating Traditional Regimens with Complementary Care: PRNewswire - October 1, 1999; NEW YORK, Oct. 1 /PRNewswire/ -- Thousands of people living with HIV/AIDS use complementary and alternative medicines (CAM) every day to enhance their health. Treatments range from vitamins, to herbs to yoga and acupuncture. But are CAM treatments safe and effective to use with the complicated pharmaceutical regimens t
American Dental Hygienists' Association: Dental Hygienists Participate In Chicago Marathon to Aid Oral Health Research: PRNewswire - September 30, 1999; CHICAGO, Sept. 30 /PRNewswire/ -- Promoting good oral health and total wellness are key goals of the American Dental Hygienists Association (ADHA) as evidenced by its long-time sponsorship of National Dental Hygiene Month (NDHM) in October. This year, ADHA will add participation in the LaSalle Banks Chicago 5K Marathon
American Red Cross Accelerates Conversion to Plas+(R)SD: PRNewswire - September 30, 1999; WASHINGTON, Sept. 30 /PRNewswire/ -- Over the next year, the American Red Cross will implement a plan to accelerate to a full conversion of fresh frozen plasma to its virus-inactivated alternative, PLAS+(R)SD (Pooled Plasma, Solvent Detergent Treated). Consistent with this conversion policy, the American Red Cross will
Chain Pharmacies Join FDA Initiative Encouraging Women to 'Take Time To Care' In Learning About Proper Prescription and OTC Medication Use - Nationwide Education Campaign Launched on the Safe Use of Medicine -: PRNewswire - September 30, 1999; WASHINGTON, Sept. 30 /PRNewswire/ -- In October, millions of women will have access to specialized information about the proper use of medications in a national public awareness campaign being jointly conducted by the U.S. Food and Drug Administration ( FDA ) and the National Association of Chain Drug Stores. An un
The American Red Cross Launches 'CARE 2000' Program Offers Increased Support for Individuals with Hemophilia Throughout the World: PRNewswire - September 30, 1999; ARLINGTON, Va., Sept. 30 /PRNewswire/ -- To increase the level of educational and therapeutic support it provides to members of the hemophilia community around the world, the American Red Cross has launched an initiative called the American Red Cross CARE 2000(TM), a multi-million dollar initiative that is the first in
VTech(R) Creates Year 2000 Calendar of Children's Art to Benefit Pediatric AIDS Chicago: PRNewswire - September 30, 1999; WHEELING, Ill., Sept. 30 /PRNewswire/ -- Dedicated to helping children, VTech, the leading manufacturer of electronic learning toys, has teamed up with Pediatric AIDS Chicago, a non-profit group that supports national pediatric AIDS research, education and hands-on care-giving organizations, to raise money through the
Vertex Partner Kissei Pharmaceutical to Launch HIV Protease Inhibitor Prozei(TM) in Japan: PRNewswire - September 30, 1999; CAMBRIDGE, Mass., Sept. 30 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Kissei Pharmaceutical Co., Ltd. (Matsumoto-City, Japan ) announced today that Kissei is launching Prozei(TM) ( amprenavir ), an orally administered HIV protease inhibitor, in Japan.
The 1999 United States Conference on AIDS To Be Held in Denver, Colorado November 4 - November 8; 3,000 Expected, Largest HIV/AIDS Meeting in the United States: PRNewswire - September 30, 1999; WHAT: The United States Conference on AIDS, the largest HIV/AIDS meeting in the US, will convene more than 3,000 community-based workers, people living with HIV, physicians, social workers, health department officials, policy makers, funders and community activists from around the nation for four days of learning, shar
Broad Coalition Urges Governor To Sign Bill Opening the Workplace to the Disabled: PRNewswire - September 29, 1999; LOS ANGELES, Sept. 29 /PRNewswire/ -- A broad coalition of state and local representatives of the disabled community urged Governor Davis to sign AB 155 (Migden), which will allow disabled individuals to return to work and maintain their health care benefits through the Medi-Cal program. The advancement in medical trea
AHF Victorious in Guaranteeing Access: Governor Signs AIDS Drug Bill (AB 1047, Marco Firebaugh, D-Los Angeles); Bill Sponsored by AIDS Healthcare Foundation Adds More FDA-Approved AIDS Drugs to State's ADAP Formulary - AHF Urges Davis to Also Sign AB 217 (Scott Wildman, D- Los Angeles) to Improve Patient Access to Quality AIDS Care in Managed Care Plans: PRNewswire - September 29, 1999; LOS ANGELES, Sept. 29 /PRNewswire/ -- In a victory for AIDS patients and care providers throughout California, Governor Gray Davis signed AB 1047 (Marco Firebaugh D Cudahy), a bill that will improve access to potentially life-saving AIDS drugs for many low and moderate income Californians. The bill, one of two AIDS Hea
New Study Shows Gatifloxacin to be An Effective and Well-Tolerated Treatment For Community-Acquired Pneumonia; In Comparison Test, Gatifloxacin Shows Edge Over Clarithromycin: PRNewswire - September 29, 1999; SAN FRANCISCO, Sept. 29 /PRNewswire/ -- The results of a multicenter Phase III study comparing the efficacy and safety of gatifloxacin to clarithromycin in treating community-acquired pneumonia (CAP) showed gatifloxacin to be more effective. The study findings were presented this week at the 39th Interscience Conferenc
Data on HIV Drug Resistance Suggest Previous Use of Viramune(R) or Rescriptor(R) May Jeopardize Use of Sustiva(TM) as Treatment Option: PRNewswire - September 29, 1999; SAN FRANCISCO, Sept. 29 /PRNewswire/ -- Data from a virology sub-study of the DuPont Pharmaceuticals Sustiva (TM) (efavirenz) Expanded Access Program indicate that 78 percent of patients who initiate combination therapy with Viramune (R) (
Isis and Rhone-Poulenc Rorer Establish Antisense Target Validation Collaboration: PRNewswire - September 29, 1999; CARLSBAD, Calif., COLLEGEVILLE, Pa. and ANTONY, France , Sept. 29 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) and Rhone-Poulenc Rorer (NYSE: RP) (RPR) announced today that they have signed a three year collaboration to assess genes identified within RPR s genomics programs using Isis Antisense Ta
Immune Response Resulting from Treatment With Agenerase(TM)+ Ziagen(R) Evaluated in Patients with Early Stage HIV Infection; Treated HIV-Positive Patients Compared to Long-Term Non-Progressors and HIV-Negative Volunteers: PRNewswire - September 28, 1999; SAN FRANCISCO, Sept. 28 /PRNewswire/ -- Results of a new phase II study with Agenerase ( amprenavir )+ Ziagen ( abacavir sulfate) during the early stage of HIV infection focu
Special HIV/AIDS Report: Data on Promising New AIDS Drug Combinations Unveiled at Major Conference: PRNewswire - September 28, 1999; SAN FRANCISCO, Sept. 28 /PRNewswire/ -- Results of two French studies that focus on simplifying HIV/AIDS treatment regimens were presented today at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting by Professor Francois Raffi, a researcher at the Centre Hospitalier Regional et Un
Data Show Anti-Viral Activity of Sustiva(TM) in Combination with D4T and DDI in Treatment-Naive Patients with High Viral Load; Data Highlight the Use of Sustiva Treatment in a Wide Variety of HIV-Infected Patients: PRNewswire - September 28, 1999; SAN FRANCISCO, Sept. 28 /PRNewswire/ -- Data presented today at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy describe anti-viral activity of DuPont Pharmaceuticals Sustiva (TM)( efavirenz ) in patients with high viral load (greater than or equal to 100,000 copies/mL
Study Demonstrates New Antifungal Agent Improves Outcomes in Adult HIV Patients with Esophageal Candidiasis; Clinical Data Demonstrate Efficacy at all Doses Tested with No Safety-Related Issues: PRNewswire - September 28, 1999; DEERFIELD, Ill, Sept. 28 /PRNewswire/ -- Fujisawa Healthcare, Inc. (Fujisawa) today announced the results of clinical trials for FK463, a systemic antifungal agent of the echinocandin class. Study results concluded that, in an AIDS population, FK463 was effective in improving or clearing clinical signs and symptoms of
Frost & Sullivan - Patient Awareness of Treatment Options Fuels Growth of HIV/AIDS Therapeutic Markets: PRNewswire - September 28, 1999; MOUNTAIN VIEW, Calif., Sept. 28 /PRNewswire/ -- Of the 40,00 people infected with HIV in the U.S. each year, certain groups, such as ethnic minorities, women, and IV drug users, are often overlooked in awareness and treatment programs. Pharmaceutical companies that target these untapped populations with treatment educa
Pharmacia & Upjohn's SUGEN Inc. Presents Results of Phase I Trial of Lead Angiogenesis Inhibitor, SU5416, in Kaposi's Sarcoma at ICAAC: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- SUGEN, Inc. today presented positive data from a dose-escalating Phase I trial of SU5416, its lead angiogenesis inhibitor, in AIDS-related Kaposi s sarcoma (KS), at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), in San Francisco, CA. Results fr
Protease Inhibitor ABT-378/r Shows Promise in Both Treatment-Naive And Treatment-Experienced HIV-Positive Patients: PRNewswire - September 27, 1999; ABBOTT PARK, Ill., Sept. 27 /PRNewswire/ -- Data from two Phase 2 studies presented today at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco suggest Abbott Laboratories (NYSE: ABT) investigational protease inhibitor, ABT-378/ ritonavir (ABT-378/r), d
Data Presented at Medical Conference on VX-175/GW433908, An HIV Protease Inhibitor Prodrug -- VX-175/GW433908 Evaluated in First Human Study --: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Early data reported for the first time today suggest that VX-175/GW433908, the prodrug of the HIV protease inhibitor amprenavir , is a candidate for further clinical evaluation. Three reports on VX-175/GW433908 covering the design of the compound, preclinical and early clinical s
New Data Present Resistance and Potency Profiles for DuPont Pharmaceuticals' Second-Generation NNRTIs; Simultaneous Development of Four Compounds Highlights Company's Aggressive Commitment to HIV Treatment: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- DuPont Pharmaceuticals today, as part of the company s commitment to find new drugs with superior potency against HIV infections, presented data from pre-clinical studies on four second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) currently in simultaneous
The Atlantic Study: Press Release: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Today researchers unveiled 48-week data from the Atlantic Study, the first trial to directly compare the effect of the three different available classes of AIDS drugs within combination regimens. Preliminary results from this ongoing multi-center international trial show that tri
Alarming Profile Emerges in Women & HIV/AIDS Prevention Battle, Researchers Say; Black and Hispanic Women Have Become Front Line Targets of Disease As Heterosexual Partners Leave Many Exposed to the HIV Virus: PRNewswire - September 27, 1999; LOS ANGELES, Sept. 27 /PRNewswire/ -- Clinical and social science researchers have found that there are many reasons for the increase in the number of reported HIV/AIDS cases among women, especially women of color. The reasons range from social to economical, behavioral to biological factors. While the mortality rate a
Phenotypic HIV Drug Resistance Testing Superior to Treatment History in Predicting Salvage Therapy Success - Late Breaker Study Presented Monday at ICAAC Uses Novel Phenotypic Assay, PhenoSense(TM) HIV -: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- A late breaker study presented today at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) by Dr. Michael Saag of the University of Alabama, Birmingham found that phenotypic HIV drug resistance testing is superior to treatment history in predicting
Triangle Pharmaceuticals Reports Preliminary Resistance Profile Data On Coactinon(R) (Emivirine) in HIV Coactive Therapy - Data Presented at 39th Annual ICAAC Meeting in San Francisco -: PRNewswire - September 27, 1999; DURHAM, N.C., Sept. 27 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that it will present promising resistance profile data on Coactinon(R) (emivirine), formerly known as MKC-442, from a laboratory study of HIV-1 mutations and sensitivity to other antivirals in HIV-infected patients who
Study Shows Safety of Oral Flu Pill Tamiflu(TM) in Elderly and High-Risk Populations; Additional Data Demonstrates Tamiflu Consistently and Significantly Reduces Flu Duration: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Hoffmann-La Roche Inc. today announced preliminary study results demonstrating the safety of Tamiflu (oseltamivir phosphate) in elderly and high-risk patients, as well as data that shows the efficacy and safety benefit of Tamiflu in the long-term prevention of influenza in elderl
48-Week Results from Pivotal Agenerase(TM) Study Presented: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Forty-eight week results from a study comparing Agenerase (TM) ( amprenavir )+ Epivir (R) (lamivudine)+Retrovir(R) (zidovudine) to a placebo+Epivir+Retrovir were presented today at the 39th Intersc
Cross-Resistance to Agenerase(TM) and Other Protease Inhibitors Assessed in Patients with Previous PI Experience: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- In vitro data from a study analyzing rates of antiviral resistance to the five currently approved protease inhibitors , including Agenerase ( amprenavir ), among heavily pre- treated patients with HIV wer
Ambisome(R) Phase III Study for Cryptococcal Meningitis in AIDS Patients Shows Promising Results; Data Suggest Equivalent Efficacy and Improved Safety Profile for AmBisome in Comparison to Amphotericin B: PRNewswire - September 27, 1999; DEERFIELD, Ill. and FOSTER CITY, Calif., Sept. 27 /PRNewswire/ -- Fujisawa Healthcare, Inc. (Fujisawa) and Gilead Sciences , Inc. (Nasdaq: GILD) today presented results from a Phase III clinical study comparing the safety and efficacy of AmBisome (liposomal amphotericin B) to conventional amphotericin B for the initial
Agouron and Immune Response Initiate Pivotal Trial of REMUNE, An Immune-Based Therapy for the Treatment of HIV Infection: PRNewswire - September 27, 1999; LA JOLLA, Calif., Sept. 27 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. and The Immune Response Corporation (Nasdaq: IMNR) today announced that a pivotal trial has been initiated to further evaluate the safety and efficacy of REMUNE(TM) (HIV-1 Immunogen), in combination with highly active antiretroviral therapy (HAART
Once-Daily Combinations of Crixivan(R) with Ritonavir Produced Blood Levels That Were Comparable to the Approved Dosing of Crixivan; New Pharmacokinetic Study Showed Blood Levels of Crixivan Boosted by Ritonavir: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- A new pharmacokinetic study of once-daily Crixivan (R) ( indinavir sulfate) combined with another protease inhibitor, ritonavir(A), showed that blood levels of Crixivan were boosted to levels that were comparable to those seen in a prior study with the app
Progenics Reports Positive Clinical Results for HIV Therapy Evidence of antiviral activity seen with single dose of drug: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) presented results of a Phase I clinical trial in which PRO 542, a novel inhibitor of HIV entry, was shown to have antiviral activity. The results were reported Sunday at the 39th Interscience Conference on Antimicrobial Agents and Ch
Triangle Pharmaceuticals Reports Data on Pharmacokinetics and Tolerability of Coactinon(R) (Emivirine) in HIV-1 Infected Pregnant Women and Their Offspring: PRNewswire - September 27, 1999; DURHAM, N.C., Sept. 27 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced that it presented preliminary data yesterday on the pharmacokinetics and tolerability of Coactinon(R) (emivirine), formerly known as MKC-442, in HIV-1 infected pregnant women and their offspring. Coactinon, Triangle s most ad
Triangle Pharmaceuticals Reports DAPD Preclinical Safety And Antiviral Activity Against Drug-Resistant HIV Strains -- Data Presented at 39th Annual ICAAC Meeting in San Francisco --: PRNewswire - September 27, 1999; DURHAM, N.C., Sept. 27 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced that it will be presenting preclinical data today on in vitro activity of DAPD against drug-resistant strains of HIV at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. Based
Sustiva(TM) Study Demonstrates New Methodology for Measuring Durability of Treatment Response in HIV; Combination Therapy with Sustiva Appears More Effective/Durable in Long-Term Suppression of Viral Load than Combination Therapy with a Protease Inhibitor: PRNewswire - September 27, 1999; SAN FRANCISCO, Sept. 27 /PRNewswire/ -- Applying a US Food and Drug Administration ( FDA )-endorsed new standard of data analysis in HIV that measures duration of treatment response, DuPont Pharmaceuticals today released the latest findings on Sustiva (TM) (
48 Week Results from Pivotal Agenerase(TM) Study Presented: PRNewswire - September 26, 1999; SAN FRANCISCO, Sept. 26 /PRNewswire/ -- Forty-eight week results from a study comparing Agenerase (TM) ( amprenavir )+ Epivir (R) (lamivudine)+ Retrovir(R) (zidovudine) to a placebo+Epivir+Retrovir were presented today at the 39th Inters
Once-Daily Dose of FORTOVASE Shows Promise in Early Study Additional Study of Once-Daily Regimen Underway To Evaluate Efficacy of a Potential New Treatment Option: PRNewswire - September 26, 1999; SAN FRANCISCO, Calif., Sept. 26 /PRNewswire/ -- Data presented today demonstrate that a once-daily (QD) dose of the protease inhibitor FORTOVASE(R) (saquinavir) in combination with a mini-dose of the protease inhibitor ritonavir significantly increases the blood level of FORTOVASE above the level currently believed to
Results Reported from Landmark HIV Study Designed to Compare Ziagen(R)+Combivir(R) to a Standard-of-Care Regimen; First 48-Week Data from Major Study of a Triple NRTI Regimen Presented: PRNewswire - September 26, 1999; SAN FRANCISCO, Sept. 26 /PRNewswire/ -- Forty-eight week data from a study comparing the triple nucleoside reverse transcriptase inhibitor (NRTI) regimen of Ziagen (abacavir sulfate)+ Combivir (lamivudine/zidovudine) to treatment with Cr
Cross Resistance to Agenerase(TM) and Other Protease Inhibitors Assessed in Patients with Previous PI Experience: PRNewswire - September 26, 1999; SAN FRANCISCO, Sept. 26 /PRNewswire/ -- In vitro data from a study analyzing rates of viral resistance to the five currently approved protease inhibitors , including Agenerase ( amprenavir ), among heavily pre-treated patients with HIV were pre
Sustiva(TM) Study Demonstrates New Methodology for Measuring Durability of Treatment Response in HIV; Combination Therapy with Sustiva Appears More Effective/Durable in Long-Term Suppression of Viral Load than Combination Therapy with a Protease Inhibitor: PRNewswire - September 26, 1999; SAN FRANCISCO, Sept. 26 /PRNewswire/ -- Applying a US Food and Drug Administration ( FDA )-endorsed new standard of data analysis in HIV that measures duration of treatment response, DuPont Pharmaceuticals today released the latest findings on Sustiva (TM) (
Biochem Pharma's Products, Compounds and Research Featured at 39th Annual ICAAC: PRNewswire - Septgember 26, 1999; LAVAL, Quebec, Canada , Sept 26 /CNW - PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE; ME, TSE: BCH) announced today that several of the Company s development or research initiatives will be the subject of oral or poster presentations at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking
Seven Studies Utilizing ViroLogic's Phenotypic HIV Drug Resistance Assay To Be Presented at The 39th Interscience Conference On Antimicrobial Agents and Chemotherapy (ICAAC) - Data Highlight Utility and Reliability of New Assay, PhenoSense(TM) HIV: PRNewswire - September 26, 1999; SOUTH SAN FRANCISCO, Calif., Sept. 26 /PRNewswire/ -- ViroLogic, Inc. s novel phenotypic HIV drug resistance assay, PhenoSense(TM) HIV, will be the subject of seven studies to be presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 26-29. Included am
Conference Organizers Ask Presidential Candidates to State Positions on HIV & Women Issues: PRNewswire - September 23, 1999; LOS ANGELES, Sept. 23 /PRNewswire/ -- In a letter sent to all presidential candidates, organizers of the 1999 National Conference on Women and HIV/AIDS (October 9-12, 1999) invited candidates to answer several questions related to social, policy, program, and research funding for HIV/AIDS issues among women. Ferd Eggan
Immune System Cells Surprisingly High in HIV-Infected Adolescents, Says Researcher at The Children's Hospital of Philadelphia: PRNewswire - September 23, 1999; PHILADELPHIA, Sept. 23 /PRNewswire/ -- Adolescents infected with HIV were found to have a surprisingly high number of certain immune system cells, according to a research team led by an immunologist at The Children s Hospital of Philadelphia. In studying 94 HIV-positive patients, aged 13 to 19, the researchers found a
Immtech International Inc. Targets Giardia and Cryptosporidium Parasites With Revolutionary Product: DAP-092: PRNewswire - September 23, 1999; EVANSTON, Ill., Sept. 23 /PRNewswire/ -- Immtech International Inc., (Nasdaq: IMMT) today announced that it will be entering into Phase I clinical trials in first quarter of 2000 with DAP-092 for the treatment of Cryptosporidium and Giardia parasitical infections. DAP-092 is designed to treat severe diarrhea and wastin
Opportunities for Gene Therapy Vary Among Cancer, Cardiovascular, HIV And Monogenic Disorders: PRNewswire - September 23, 1999; FOSTER CITY, Calif., Sept. 23 /PRNewswire/ -- Worldwide sales for the gene therapy market is expected to reach a total of $4.8 million by 2008. Gene therapy products in development primarily target cancer, with a lower emphasis on HIV, cardiovascular, cystic fibrosis, hemophilia A and Gaucher s disease. Future trends i
New Studies on Drug-Resistant HIV Using ViroLogic's PhenoSense(TM) HIV Assay Demonstrate Advantages of Phenotypic HIV Drug Resistance Testing - Results Published in the Journal of the American Medical Association -: PRNewswire - September 22, 1999; SOUTH SAN FRANCISCO, Calif., Sept. 22 /PRNewswire/ -- Up to 28% of newly infected individuals may contract HIV that is resistant to one or more anti-AIDS drugs, according to two studies published today in the Journal of the American Medical Association . The studies were carried out by various medical research institut
New Patch to Treat Nerve Pain After Shingles Now Available; Endo Pharmaceuticals Launches Lidoderm(R) for Postherpetic Neuralgia Pain: PRNewswire - September 22, 1999; CHADDS FORD, Pa., Sept. 22 /PRNewswire/ -- Starting today, a new patch medication to treat the chronic nerve pain often experienced after a case of shingles will be available in pharmacies nationwide, according to product marketer Endo Pharmaceuticals, Inc. of Chadds Ford, Pennsylvania. (Photo: NewsCom: http://www.news
Revolutionary New Condom to Encourage Condom Usage During 'National Condom Month' and Beyond; New Latex-Free Trojan Supra(TM) Microsheer(TM) Polyurethane Condom Transmits Body Heat for Your Ultimate Sensual Pleasure: PRNewswire - September 22, 1999; NEW YORK, Sept. 22 /PRNewswire/ -- Just in time for National Condom Month (October), industry leader Trojan(R) brand condoms is hitting the shelves with one of the most significant advances in the condom industry since the development of latex in the 1930s -- new Trojan Supra(TM) Microsheer(TM) Polyurethane condoms. T
FDA Advisory Committee Recommends Reclassification of HIV Genotyping Drug Resistance Assays to Class II with Special Controls -- Reclassification Could Pave the Way for More Targeted HIV Treatments --: PRNewswire - September 20, 1999; TORONTO, Sept. 20 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN) reported today that on Friday the U.S. Food and Drug Administration s ( FDA ) Blood Products Advisory Committee (BPAC) recommended the reclassification of all HIV genotyping drug resistance assays from Class III to Class II with special contro
Playboy to Allow Historic First Sale of a Bunny Costume to Benefit Aids Research; Company to Host Benefit Cocktail Supper Hugh Hefner to Donate Pajamas: PRNewswire - September 17, 1999; NEW YORK, Sept. 17 /PRNewswire/ -- Playboy Enterprises announced today that it would host an exclusive cocktail supper to benefit the New York based AIDS research organization, Community Research Initiative on AIDS (CRIA). The September 22nd dinner will celebrate Playboy s participation in Sotheby s Fashion department
Boston to New York AIDS Ride 5 Presented by Tanqueray to Continue Bicycling Trek From New Haven to Bridgeport After Hurricane Delays: PRNewswire - September 17, 1999; NEW HAVEN, Conn., Sept. 17 /PRNewswire/ -- The Boston to New York AIDS Ride 5 Presented By Tanqueray, which was cancelled yesterday for the first day of the three-day bicycling trek because of Hurricane Floyd, will continue today for a portion of the route. Over 2,550 Riders who raised $7 million for AIDS services in B
U.S. Rep. Barbara Lee (D-CA) and Bristol-Myers Squibb Receive Awards For African AIDS Leadership Programs: PRNewswire - September 17, 1999; WASHINGTON, Sept. 17 /PRNewswire/ -- The Constituency for Africa (CFA) and the Ronald H. Brown Foundation today honored Congresswoman Barbara Lee (D-CA) and Bristol-Myers Squibb Company in recognition of two historic African AIDS/HIV initiatives. Rep. Lee was honored for introducing legislation to fund the AIDS Marshal
African AIDS Leadership Programs to be Recognized at Luncheon: PRNewswire - September 17, 1999; The Constituency for Africa (CFA) and the Ronald H. Brown Foundation Laud Marshall Plan for Africa Legislative Initiative and Secure the Future Program with its Constituent of the Year Award WHAT: The Constituency for Africa (CFA) and the Ronald H. Brown Foundation will honor Congresswoman Barbara Lee (D-CA) and
Rev. Dr. Calvin 0. Butts, III Will Take HIV/AIDS Test at Public Health Expo to Promote Community Health Awareness; Special Program Will Feature Celebrities and Leaders: PRNewswire - September 15, 1999; Reverend Dr. Calvin 0. Butts, III, Senior Pastor of the Abyssinian Baptist Church, will undergo screening tests for multiple chronic diseases -- ranging from high blood pressure to HIV/AIDS -- as a demonstration of his personal support for this week s Harlem Health Expo, a free public health education program sponsored
Cell Genesys Reacquires Product Rights for AIDS Gene Therapy Encouraging Phase II Trial Data Reported: PRNewswire - September 15, 1999; FOSTER CITY, Calif., Sept. 15 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that the company has reacquired product rights to its AIDS gene therapy program following the termination of a collaboration agreement with Hoechst Marion Roussel, Inc. The agreement has provided funding for Cell Genesys AID
National Black Leadership Commission on AIDS Launches Health Expo in Harlem To Raise Awareness of HIV/AIDS in the African-American Community: PRNewswire - September 15, 1999; NEW YORK, Sept. 15 /PRNewswire/ -- The National Black Leadership Commission on AIDS (BLCA) today launched Break the Silence, a major public health initiative designed to raise awareness of HIV/AIDS and to promote HIV prevention, testing and treatment in the African-American community. The Health Expo, a free educationa
AIDS Project Los Angeles Applauds California State Legislature For Passing Important HIV/AIDS Bills; APLA Urges Governor Davis to Quickly Sign Bills Into Law: PRNewswire - September 10, 1999; LOS ANGELES, Sept. 10 /PRNewswire/ -- AIDS Project Los Angeles (APLA) applauds the California State Legislature for passing AB 155, AB 103 and AB 136, three important HIV/AIDS bills, and urges Governor Gray Davis to expeditiously sign the bills into law. APLA, on its own and in collaboration with various other organiza
Study Finds That HPV Testing is More Accurate Than the Pap Smear: PRNewswire - September 18, 1999; BELTSVILLE, Md., Sept. 10 /PRNewswire/ -- A paper published today in the British Journal of Cancer shows that testing for the human papillomavirus (HPV), the virus that causes cervical cancer, is a more accurate method than the Pap smear for identifying women with cervical disease. The study, conducted by the Imperial
Artists Unite in the Fight Against AIDS; For the Midwest AIDS Prevention Project: PRNewswire - September 9, 1999; FERNDALE, Mich., Sept. 9 /PRNewswire/ -- More than 100 of Detroit s most prominent artists will donate pieces of original art to be auctioned at the fourth annual ART WORKS FOR LIFE AIDS benefit. This exciting event will begin at 6:30 p.m. on Saturday, September 18, 1999 at the Edsel and Eleanor Ford House in Grosse Po
Expanded Access of Chiron's Macrolin IL-2 in France for Treatment of HIV-Infected Patients: PRNewswire - September 9, 1999; AMERSTERDAM, the Netherlands , Sept. 9 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) today announced that the French Ministry of Health (AFSSAPS) has granted an Authorization for Temporary Use (ATU) of Macrolin* IL-2 for the treatment of people with advanced HIV infection, who despite effective anti-retroviral trea
New FDA HIV Approval is Good News for Patients and Physicians: PRNewswire - Wednesday September 8, 1999; WASHINGTON, Sept. 8 /PRNewswire/ -- The recent stavudine ( d4T or Zerit ) and didanosine (ddI or Videx ) approval by the Food and Drug Administration is good news for patients and their doctors according to the National Association of
French Heiress Calls on World's Richest to Save 40 million AIDS Orphans Orphans and HIV: The Second Wave of the HIV Epidemic: PRNewswire - September 7, 1999; MONTREAL, Sept. 7 /PRNewswire/ -- At 8:30 a.m. on Sunday, September 5 at the Hotel du Parc, Montreal, at the Conference of Global Strategies for the Prevention of HIV Transmission from Mothers to Children, a French Countess who devotes her time and fortune to saving children orphaned by AIDS, will call upon the world s
Hughes Institute Scientists Report Further Progress in Efforts to Improve Drug Therapies for HIV: PRNewswire - September 7, 1999; MINNEAPOLIS, Sept. 7 /PRNewswire/ -- In a continuation of efforts to improve drug therapies for HIV, Hughes Institute scientists report the development of a series of drugs which show remarkable activity against all HIV strains tested. The results of this research, reported in this month s issue of Antiviral Chemistry
ViroLogic Study Demonstrates Potential Clinical Utility of HIV Phenotypic Drug Resistance Testing - Results Published in September Issue of Journal of Infectious Diseases -: PRNewswire - September 7, 1999; SOUTH SAN FRANCISCO, Calif., Sept. 7 /PRNewswire/ -- Phenotypic HIV drug susceptibility testing can provide an early warning of HIV drug resistance before combination drug therapy fails, according to a clinical research article published in the September issue of the Journal of Infectious Diseases (http://www.journals.
'Break the Silence' - A Major Public Health Initiative At the Abyssinian Baptist Church: PRNewswire - September 7, 199; According to 1998 New York State Department of Health data, African-Americans accounted for 51% of all reported AIDS cases in the city of New York even though they only make up 25% of the city s population. Why does the HIV/AIDS epidemic affect the African-American community at such an alarming rate? Come join the Nati
Second Regional Update Conference on African-Americans and AIDS New York, September 14: PRNewswire - September 7, 1999; Regional Update Conferences on African-Americans and AIDS have been organized to focus on HIV/AIDS in the African-American community. WHAT: Leading AIDS experts from the medical, research, government and public health sectors will address a wide range of issues relating to African-Americans and AIDS. Presentations at t
Study of the Immune Response Corporation's Remune in Children Suggests Sustained Reduction of Viral Load; Preliminary Results of Two Studies Reported in Peer-Reviewed Journal: PRNewswire - September 7, 1999; CARLSBAD, Calif., Sept. 7 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced that data from two U.S. Remune(TM) trials appeared in the September issue of the peer-reviewed scientific publication, The Journal of Infectious Diseases, Vol. 180(3), 1999. The preliminary results of a Phase 1 stud
Fighting to Save Nurses' Lives -- ONA Supports Legislation Requiring Safe Needles in Ohio Public Health Care Facilities: PRNewswire - September 3, 1999; COLUMBUS, Ohio, Sept. 3 -- The technology exists to protect registered nurses and other health care workers from deadly needlestick injuries, yet less than 15 percent of U.S. hospitals use safe needle devices -- putting health care workers at risk for contracting life-threatening infections such as HIV and Hepatitis C.
AIDS Healthcare Foundation Declares AIDS MediCal Bill Will Die In San Francisco Legislator's Committee Today; AIDS Activists Decry Carole Migden's Failure to Pass Life-Saving Bill That She Had Previously Supported: PRNewswire - September 3, 1999; LOS ANGELES, Sept. 3 -- AIDS activists expressed dismay and anger at California State Assembly Member Carole Migden (D, San Francisco) for her failure to use her leadership on the Assembly Appropriations Committee to help pass SB 1258. The measure, by State Senator Richard Polanco (D, Los Angeles), would have directed
Bristol-Myers Squibb and the Government of South Africa Announce Partnership to Address HIV/AIDS: PRNewswire - September 3, 1999; JOHANNESBURG, South Africa and NEW YORK, Sept. 3 -- Bristol-Myers Squibb Company (NYSE: BMY) and the Government of South Africa today announced that Bristol-Myers Squibb is joining the South African Partnership Against AIDS and will collaborate with the Department of Health to achieve the goals of the Secure The Future
NATAP HIV/HCV Radio Show on WOR Radio 710 AM in NYC, 11 PM Sunday; This week's topic: 4 Patients Discuss Their Experience with HCV Treatment: PRNewswire - September 3, 1999; NEW YORK, Sept. 3 /PRNewswire/ -- Jules Levin, the Executive Director of the National AIDS treatment Advocacy Project, is the host/producer for a new concept in talk radio. Every Sunday night from 11 PM to 12 Midnight Jules will host Living Well With HIV, a talk interview show on current HIV and hepatitis treatment iss
AIDS Experts Gather at the Second International Conference to Address Obstacles and Solutions Related to the Spread of HIV: PRNewswire - September 2, 1999; NEW YORK, Sept. 2 -- The second international conference on global strategies for the prevention of HIV transmission from mothers to infants is being held in Montreal, Canada . This information is provided by The American Foundation for AIDS Research (amfAR). (Video: http://www.prnewswire.com/orbis/2848/jump_public.htm
The Liposome Company Receives FDA Approval for ABELCET(R) 50-Milligram Vial: PRNewswire - September 2, 1999; PRINCETON, N.J., Sept. 2 -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that it has received marketing approval for its 50-milligram ABELCET(R) (Amphotericin B Lipid Complex Injection) vial from the Food and Drug Administration. The 50-milligram vial will also be available in the
The Elizabeth Glaser Pediatric AIDS Foundation Endorses 'Call to Action' To Prevent HIV Infection in Newborns Worldwide; $1 Million Donation Made to Initiate Action: PRNewswire - September 1, 1999; LOS ANGELES, Sept. 1 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation has signed on to the Call to Action issued today at the Montreal meeting Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. To demonstrate its support, the Foundation committed $1 million to mobilize a wor
One Million Additional Infants Will Be Infected with HIV by 2003 If Prevention Measures Not Taken, Announces Global AIDS Conference in Montreal; As Many as 45% of Pregnant Women in Regions of South Africa Will Be HIV Infected by 2000; India Projected to Surpass Continent of Africa in HIV Infections in Next Decade; Ethics Shift Dramatically with New Prevention Therapies: PRNewswire - September 1, 1999; MONTREAL, Sept. 1 /PRNewswire/ -- If prevention methods are implemented immediately, more than one million additional HIV infant infections can be prevented by 2003, predicted researchers today at the second Global Strategies for the Prevention of HIV Transmission from Mothers to Infants conference opening in Montreal
St. Jude Researchers Discover Genetic Reason Why Some Patients Resist HIV Therapy; Study Sheds Light on How Cells Evade Anti-HIV Drugs in Absence Of Drug-Resistant Virus: PRNewswire - August 30, 1999; MEMPHIS, Tenn., Aug. 30 /PRNewswire/ -- The gene MRP4 appears to help T cells, key components of the human immune system, pump out certain anti-HIV drugs and may allow the development of drug-resistant strains of HIV, report a team of St. Jude Children s Research Hospital scientists in the September issue of Nature Med
The Female Health Company Receives Significant New Volume Order For Female Condoms in Brazil; Two-Million-Unit Purchase Marks a Significant Milestone in the Company's Strategy for Growth; Order is Based on Strong Success of One-Year Pilot Project: PRNewswire - August 27, 1999; CHICAGO, Aug. 27 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced it has been awarded a significant contract for the purchase of 2 million female condoms from the Brazilian Ministry of Health. The order is part of the Brazilian government s national AIDS prevention program supported
Mother-To-Infant HIV Transmission Solutions Exist Yet Significant Barriers to Progress Remain; Global Strategies Conference to Explore Bringing Solutions to Developing World, to Prevent Exploding Infection Rates: PRNewswire - August 25, 1999; WHAT: The developed world has experienced a decline in mother-to-child HIV transmission with fewer than 300 infants born every year with HIV in the U.S., however, rates of mother-to-child infection in the developing world including India , China and Africa continue to rise. Worldwide, more than 1,600 infants a day are
AIDS Project Los Angeles Applauds State Senate for Passing Legislation Allowing Local Communities Needle and Syringe Exchange: PRNewswire - August 24, 1999; LOS ANGELES, Aug. 24 /PRNewswire/ -- AIDS Project Los Angeles (APLA) applauds the State Senate on its passage of Assembly Bill 518, legislation that will allow local communities to enact clean needle and syringe exchange projects as part of a network of comprehensive HIV services for injection drug users. Injection dru
Texas AIDS Health Fraud Information Network Offers Free Training to AIDS Organizations; TAHFIN Teaches AIDS Service Providers About Potentially Misleading And Dangerous Treatment Claims: PRNewswire - August 24, 1999; DALLAS, Aug. 24 /PRNewswire/ -- The HIV epidemic has created business opportunities for many people. In many cases, people and companies pursue these opportunities with the sincere intention of helping while staying within the bounds of the law and maintaining fiscal integrity. The same motives can sometimes lead to ha
The Liposome Company Receives Regulatory Approval for Abelcet(R) in Belgium: PRNewswire - August 24, 1999; PRINCETON, N.J., Aug. 24 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that it has received regulatory approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) from the Ministry of Health in Belgium . The indication for ABELCET(R) is for the treatment of invasive fungal infections in
Florida Dept. Of Insurance: Firm Accused Of Deception In Viatical Probe: PRNewswire - August 23, 1999; TALLAHASSEE, Fla., Aug. 23 /PRNewswire/ -- State Treasurer and Insurance Commissioner Bill Nelson today charged deception and misrepresentation by a South Florida firm dealing in viatical products, which is the sale-and-resale of life insurance policies, usually of the terminally ill. In an order issued today, Nelson g
HIV Prevention in Drug-Using Populations is Focus Of Global Research Network Meeting - August 26-29, 1999 - Atlanta, Georgia: PRNewswire - August 23, 1999; Despite the scientific advances, the spread of injection drug use and the resultant increase in HIV transmission continue. Worldwide, 129 countries and territories now report injecting drug use, with 109 countries reporting HIV or AIDS in the drug-using population. The collective evidence presented at the 1998 Global R
Pelosi and 20 Other Californian Members of Congress Call on Governor Davis to Support Needle Exchange Bill (AB 518): PRNewswire - August 19, 1999; LOS ANGELES, Aug. 19 /PRNewswire/ -- Rep. Nancy Pelosi (D-CA) and 20 other members of California s Congressional delegation today sent Governor Gray Davis a letter urging him to support AB 518, the state legislation introduced by Assembly Member Kerry Mazzoni, that would allow local governments in California to establi
First-Ever National Conference to Assess State of U.S. HIV Prevention - Atlanta Meeting, August 29-September 1, 1999, is First to Bring Together Leading Professionals to Assess Advances in Efforts to Track and Control HIV -: PRNewswire - August 20, 1999; ATLANTA, Aug. 20 /PRNewswire/ -- More than 2,000 leading scientists, researchers and policy analysts will gather at the Hyatt Regency hotel in Atlanta for the National HIV Prevention Conference, the first meeting of its kind exclusively devoted to scientific efforts to monitor and prevent HIV in the US. The conference
New Generation of Drugs to Treat HIV Being Tested at Rush Chicago Medical Center One of 16 in the Nation to Participate in New Clinical Trial: PRNewswire - August 20, 1999; CHICAGO, Aug. 20 /PRNewswire/ -- New protease inhibitors that can treat HIV patients are currently being tested around the world and Rush-Presbyterian-St. Luke s Medical Center in Chicago is one of 16 medical centers in the country participating in a new study that doctors hope will continue the string of successes dru
VITEX Files With the FDA to Commence Clinical Trials of New "Universal" Plasma Product Reduces the Need for Blood Typing of Plasma: PRNewswire - August 12, 1999; MELVILLE, N.Y., Aug. 12 /PRNewswire/ -- V. I. Technologies, Inc. (Nasdaq: VITX) announced today that the Company has filed an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration ( FDA ) to commence trials of a new version of PLAS+SD which removes the antibodies that cause plasma to be bl
Chiron Announces Phase III Clinical Trial Evaluating Proleukin(R) In Combination With HIV Therapy; Trial to Establish the Role of Proleukin(R) in Delaying the Progression Of AIDS in HIV-Infected Patients: PRNewswire - August 18, 1999; EMERYVILLE, Calif., Aug. 18 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) announced today that it is enrolling patients in its international Phase III study, called SILCAAT, evaluating the safety and effectiveness of Proleukin(R) (aldesleukin) Interleukin-2 in combination with standard anti-HIV therapy in people li
Paramount's Emmy-Winning 'FRASIER' Begins Production on the Seventh Season; First Filming of Seventh Season to Benefit amfAR: PRNewswire - August 17, 1999; HOLLYWOOD, Calif., Aug. 17 /PRNewswire/ -- FRASIER, the sophisticated Emmy Award-winning series from Grub Street Productions in association with Paramount Network Television, begins production this week on its seventh season for NBC-TV. FRASIER, which made history with its record-breaking five consecutive Emmy Awards f
1BT.com Teams Up With the Giants to Help Fight AIDS Local Office Products and Services Company Focuses on the Community: PRNewswire - August 11, 1999; SAN FRANCISCO, Aug. 11 /PRNewswire/ -- One Business Team (1BT.com), a leading e-commerce provider of office products and services exclusively for small-to-medium sized businesses, today announced that they will be one of the sponsors of Until There s A Cure Day at 3Com Park on Sunday, August 15th, a day devoted to find
Weekly HIV Treatment Radio Talk Show: PRNewswire - August 16, 1999; NEW YORK, Aug. 16 /PRNewswire/ -- Every Sunday August 22 on WOR Radio 710 in NYC at 11 PM to 12 Midnight, Living Well with HIV will be on the air. Its a new concept in talk radio. The focus will be in-depth discussions of HIV and hepatitis treatment issues. Each week will be a new cutting edge topic and will have a lea
The Immune Response Corporation Announces REMUNE Clinical Trial in South America: PRNewswire - August 12, 1999; CARLSBAD, Calif., Aug. 12 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced its Latin American corporate partner, Roemmers Laboratory (formerly Viru-Tech), is conducting a REMUNE(TM) Phase 2 clinical trial in South America. This 28-week clinical trial is being conducted by GEMA (Grupo de Es
State of Florida Signs Largest Disease Management Contract in Nation with AIDS Healthcare Foundation 7,500 Medicaid Recipients to Benefit from Program: PRNewswire - August 11, 1999; LOS ANGELES, Aug. 11 /PRNewswire/ -- The State of Florida s Agency for Health Care Administration (AHCA) has contracted with Los Angeles-based AIDS Healthcare Foundation (AHF) to create a new disease management program for 7,500 Medicaid recipients who are afflicted with the AIDS virus. The program, called Positive Hea
Thermo BioAnalysis Subsidiary to Co-market Vaginitis Tests with Cooper Companies: PRNewswire - August 10, 1999; SANTA FE, N.M., Aug. 10 /PRNewswire/ -- Thermo BioAnalysis Corporation (Amex: TBA), a Thermo Electron company, today announced that its BioStar, Inc. subsidiary has agreed with CooperSurgical, Inc. (CSI) to co-market, on a non- exclusive basis, three physician-office diagnostic tests for vaginitis, a condition that res
Excite@Home Takes This Year's Macy's Passport '99 Online: PRNewswire - August 10, 1999; REDWOOD CITY, Calif. and SAN FRANCISCO, Aug. 10 /PRNewswire/ -- Excite@Home (Nasdaq: ATHM) today announced that it will create an interactive entertainment site for this year s Macy s Passport 99 Extreme event series, marking the first time an Internet portal is sponsoring and hosting an online presence for the interna
European Committee for Proprietary Medicinal Products Adopts Positive Opinion For Reformulated Norvir(R) (Ritonavir) Capsules: PRNewswire - August 10, 1999; ABBOTT PARK, Ill., Aug. 10 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) today announced that the European Union s Committee for Proprietary Medicinal Products (CPMP) has adopted a positive opinion on Norvir (R) ( ritonavir ) soft capsules.
Elizabeth Glaser Pediatric AIDS Foundation on JAMA Study By CDC on Perinatal Transmission of HIV: 'Great Progress, But It's Not Over': PRNewswire - August 10, 1999; SANTA MONICA, Calif., Aug. 10 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation greeted with pleasure the August 11 publication of a new study by the Centers for Disease Control and Prevention on sharp reductions in the number of pediatric AIDS cases in the U.S. This is great progress. We ve worked toward
BioChem Pharma succeeds in invalidating Emory University Australian Patent Application Relating to 3TC: PRNewswire - August 6, 1999; LAVAL, Quebec, Canada , August 6 /CNW-PRN/ - BioChem Pharma Inc. (NASDAQ: BCHE; Montreal Exchange and The Toronto Stock Exchange: BCH) announced today that the Opposition Division of the Australian Patent Office (APO) rejected Emory University s patent application (APO 658136) relating to
LifeStyles Ad Campaign Pushes The Envelope Again; New Link Between Sports And Sex: PRNewswire - August 5, 1999; RED BANK, N.J., Aug. 5 /PRNewswire/ -- LifeStyles(R) condoms is launching its new advertising campaign linking one of the nation s favorite passions -- sports -- with one of its oldest themes -- sexual frustration. The new LifeStyles ad campaign line, Haven t gotten any lately? with its image of blue colored athletic b
AIDS Healthcare Foundation Files Additional Lawsuit Against City Of Los Angeles over Mismanagement of AIDS Housing Program; Conflict of Interest by Committee Involved in Awarding HOPWA Funds At Heart of Superior Court Suit: PRNewswire - August 4, 1999; LOS ANGELES, Aug. 4 /PRNewswire/ -- In a press conference at AIDS Healthcare Foundation s (AHF s) Hollywood headquarters, AIDS and homeless activists led by AHF president Michael Weinstein today announced the filing of an additional lawsuit against the City of Los Angeles over the City s gross mismanagement of the city
Karen Ignagni Calls on Congress to Address Medicare Crisis In Testimony Before House Commerce Committee; Medicare Fairness Gap Puts Access, Benefits for Millions Of Beneficiaries in Jeopardy: PRNewswire - August 4, 1999; WASHINGTON, Aug. 4 /PRNewswire/ -- Testifying today before the House Commerce Committee s Subcommittee on Health and the Environment, AAHP President & CEO Karen Ignagni called on Congress to act this year to address the crisis in the Medicare+Choice program and preserve choices and important benefits -- including p
Paranoia or Hard Facts? Decide at 4ConspiracyTheories.com Explore the Widest Web of Lies, Cover-ups, Red Herrings and Obsessions: PRNewswire - August 4, 1999; WAYNE, Pa., Aug. 4 /PRNewswire/ -- The editors at 4anything.com, having worked in secrecy, today declassified the location where curiosity seekers can find the best resources for the most famous, compelling and beguiling obsessions of the century -- 4ConspiracyTheories.com. The site where Just because you re paranoid d
This upcoming Sunday Aug. 8, NATAP's Weekly Radio Show Topic is Immune Based Therapies on WOR Radio 710 AM in NYC: PRNewswire - August 4, 1999; NEW YORK, Aug. 4 /PRNewswire/ -- Every Sunday night at 11 PM to 12 Midnight on WOR Jules Levin hosts Living Well With HIV. A new concept in talk radio. The show explores a different topic every week with a guest researcher. This Sunday the guests include Dr Fred Valentine, an immunologist an NYU/Bellevue Medical Center
European Approval of Vitravene Triggers $2.5 MM Milestone for Isis: PRNewswire - August 4, 1999; CARLSBAD, Calif., Aug. 4 /PRNewswire/ -- Vitravene(TM), the antiviral drug developed by Isis Pharmaceuticals (Nasdaq: ISIP) and marketed by CIBAVision, has been approved by European regulatory authorities. Isis and CIBAVision Corporation, the eye care unit of Novartis AG, a leading world sciences company have been info
TeleSpectrum Worldwide Announces On-Line Alliance With Drug Emporium - TeleServices Provider to Enhance Customer Service and Satisfaction For On-Line Drug Retailer -: PRNewswire - August 4, 1999; KING OF PRUSSIA, Pa. and POWELL, Ohio, Aug. 4 /PRNewswire/ -- TeleSpectrum Worldwide Inc. (Nasdaq: TLSP) announced today they have agreed to establish a long-term strategic alliance with Drug Emporium, Inc. s (Nasdaq: DEMP) online venture, DrugEmporium.com. The new on-line store, which will be re-launched in August, wi
National Cancer Institute Acquires New SGI Supercomputer to Aid Cancer Research Efforts: PRNewswire - August 4, 1999; MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire/ -- SGI (NYSE: SGI) today announced that the National Cancer Institute (NCI) will acquire a Cray SV1(TM) supercomputer to help NCI scientists accelerate research into the causes and treatments for life-threatening diseases such as cancer, AIDS and Alzheimer s disease. NCI chose
HIV Experts Convene in Los Angeles for Regional Conference on HIV/AIDS in the African-American Community: PRNewswire - Tuesday August 3, 1999; LOS ANGELES, Aug. 3 /PRNewswire/ -- A regional conference that brings together experts from the public health sector, AIDS service organizations, and medical providers who provide care for African-Americans will convene in Los Angeles tomorrow to focus on HIV/AIDS in the African-American community. The conference is th
The Female Health Company Receives Order for 900,000 Additional Female Condoms for South Africa: PRNewswire - August 2, 1999; CHICAGO, Aug. 2 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it received an order from the Province of Mpumalanga in South Africa for 900,000 Female Condoms. Mpumalanga, one of 9 provinces in South Africa, has a population of approximately 3 million people. According to
Cell Genesys Reports Enhanced Safety Features of Lentiviral Vectors For Hemophilia Gene Therapy: PRNewswire - July 29, 1999; FOSTER CITY, Calif., July 29 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today reported that the company has developed a third-generation lentiviral gene delivery system with an improved safety profile for patients with hemophilia and other patients at risk for human immunodeficiency virus (HIV) infection. In a n
Chil